JOHNSON & JOHNSON, 10-Q filed on 4/23/2025
Quarterly Report
v3.25.1
Cover - shares
 3 Months Ended
Mar. 30, 2025
Apr. 18, 2025
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 30, 2025  
Document Transition Report false  
Entity File Number 1-3215  
Entity Registrant Name Johnson & Johnson  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1024240  
Entity Address, Address Line One One Johnson & Johnson Plaza  
Entity Address, City or Town New Brunswick  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08933  
City Area Code 732  
Local Phone Number 524-0400  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,406,073,279
Entity Central Index Key 0000200406  
Current Fiscal Year End Date --12-28  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Common Stock, Par Value $1.00    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, Par Value $1.00  
Trading Symbol JNJ  
Security Exchange Name NYSE  
1.150% Notes Due November 2028    
Entity Information [Line Items]    
Title of 12(b) Security 1.150% Notes Due November 2028  
Trading Symbol JNJ28  
Security Exchange Name NYSE  
2.700% Notes Due February 2029    
Entity Information [Line Items]    
Title of 12(b) Security 2.700% Notes Due February 2029  
Trading Symbol JNJ29B  
Security Exchange Name NYSE  
3.20% Notes Due November 2032    
Entity Information [Line Items]    
Title of 12(b) Security 3.200% Notes Due June 2032  
Trading Symbol JNJ32  
Security Exchange Name NYSE  
3.050% Notes Due February 2033    
Entity Information [Line Items]    
Title of 12(b) Security 3.050% Notes Due February 2033  
Trading Symbol JNJ33B  
Security Exchange Name NYSE  
1.650% Notes Due May 2035    
Entity Information [Line Items]    
Title of 12(b) Security 1.650% Notes Due May 2035  
Trading Symbol JNJ35  
Security Exchange Name NYSE  
3.350% Notes Due November 2036    
Entity Information [Line Items]    
Title of 12(b) Security 3.350% Notes Due June 2036  
Trading Symbol JNJ36A  
Security Exchange Name NYSE  
3.350% Notes Due February 2037    
Entity Information [Line Items]    
Title of 12(b) Security 3.350% Notes Due February 2037  
Trading Symbol JNJ37B  
Security Exchange Name NYSE  
3.550% Notes Due November 2044    
Entity Information [Line Items]    
Title of 12(b) Security 3.550% Notes Due June 2044  
Trading Symbol JNJ44  
Security Exchange Name NYSE  
3.600% Notes Due February 2045    
Entity Information [Line Items]    
Title of 12(b) Security 3.600% Notes Due February 2045  
Trading Symbol JNJ45  
Security Exchange Name NYSE  
3.700% Notes Due February 2055    
Entity Information [Line Items]    
Title of 12(b) Security 3.700% Notes Due February 2055  
Trading Symbol JNJ55  
Security Exchange Name NYSE  
v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 30, 2025
Dec. 29, 2024
Current assets:    
Cash and cash equivalents (Note 4) $ 38,474 $ 24,105
Marketable securities 307 417
Accounts receivable, trade, less allowances $170 (2024, $167) 16,020 14,842
Inventories (Note 2) 12,659 12,444
Prepaid expenses and other 4,091 4,085
Total current assets 71,551 55,893
Property, plant and equipment at cost 49,884 48,768
Less: accumulated depreciation (29,013) (28,250)
Property, plant and equipment, net 20,871 20,518
Intangible assets, net (Note 3) 36,755 37,618
Goodwill (Note 3) 44,468 44,200
Deferred taxes on income (Note 5) 8,492 10,461
Other assets 11,534 11,414
Total assets 193,671 180,104
Current liabilities:    
Loans and notes payable 13,897 5,983
Accounts payable 9,545 10,311
Accrued liabilities 7,913 8,549
Accrued rebates, returns and promotions 18,780 17,580
Accrued compensation and employee related obligations 2,551 4,126
Accrued taxes on income (Note 5) 4,217 3,772
Total current liabilities 56,903 50,321
Long-term debt (Note 4) 38,355 30,651
Deferred taxes on income (Note 5) 2,428 2,448
Employee related obligations (Note 6) 7,046 7,255
Long-term taxes payable (Note 5) 395 390
Other liabilities 10,435 17,549
Total liabilities 115,562 108,614
Commitments and Contingencies (Note 11)
Shareholders’ equity:    
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120
Accumulated other comprehensive income (loss) (Note 7) (11,740) (11,741)
Retained earnings and Additional paid-in capital 162,635 155,791
Less: common stock held in treasury, at cost (714,218,000 and 712,921,000 shares) 75,906 75,680
Total shareholders’ equity 78,109 71,490
Total shareholders’ equity 78,109 71,490
Total liabilities and shareholders’ equity $ 193,671 $ 180,104
v3.25.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 30, 2025
Dec. 29, 2024
Current assets:    
Allowances for doubtful accounts $ 170 $ 167
Shareholders' equity:    
Common stock, par value per share (in usd per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 4,320,000,000 4,320,000,000
Common stock, shares issued (in shares) 3,119,843,000 3,119,843,000
Treasury stock (in shares) 714,218,000 712,921,000
v3.25.1
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Sales to customers (Note 9) $ 21,893 $ 21,383
Sales to customers percent to sales 100.00% 100.00%
Cost of products sold $ 7,357 $ 6,511
Cost of products sold percent to sales 33.60% 30.40%
Gross profit $ 14,536 $ 14,872
Gross Profit Percent To Sales 66.40% 69.60%
Selling, marketing and administrative expenses $ 5,112 $ 5,257
Selling marketing and administrative expenses percent to sales 23.30% 24.60%
Research and development expense $ 3,225 $ 3,542
Research and development expense percent to sales 14.70% 16.60%
Interest income $ (332) $ (364)
Interest income percent to sales (1.50%) (1.70%)
Interest expense, net of portion capitalized $ 204 $ 155
Interest expense, net of portion capitalized percent to sales 0.90% 0.70%
Other (income) expense, net $ (7,321) $ 2,404
Other (income) expense, net percent to sales (33.40%) 11.20%
Restructuring (Note 12) $ 17 $ 164
Restructuring charge percent to sales 0.10% 0.80%
Earnings before provision for taxes on income $ 13,631 $ 3,714
Earnings before provision for taxes on income percent to sales 62.30% 17.40%
Provision for taxes on income (Note 5) $ 2,632 $ 459
Provision for taxes on income percent to sales 12.10% 2.20%
Net earnings from continuing operations percent of sales 50.20% 15.20%
Net earnings $ 10,999 $ 3,255
NET EARNINGS PER SHARE    
Total net earnings per share - basic (in dollars per share) $ 4.57 $ 1.35
Total net earnings per share - diluted (in dollars per share) $ 4.54 $ 1.34
Avg. shares outstanding    
Basic (shares) 2,407.2 2,408.2
Diluted (shares) 2,423.8 2,430.1
v3.25.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Net earnings $ 10,999 $ 3,255
Other comprehensive income (loss), net of tax    
Foreign currency translation (575) 2,123
Securities:    
Unrealized holding gain (loss) arising during period 0 2
Net change 0 2
Employee benefit plans:    
Prior service cost amortization during period (35) (16)
Gain (loss) amortization during period 77 68
Net change 42 52
Derivatives & hedges:    
Unrealized gain (loss) arising during period (142) (167)
Reclassifications to earnings 676 (251)
Net change 534 (418)
Other comprehensive income (loss) 1 1,759
Comprehensive income $ 11,000 $ 5,014
v3.25.1
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Foreign currency translation adjustment income (loss) $ 400 $ (619)
Employee benefit plans income (loss) 11 (42)
Derivatives & hedges income (loss) $ 142 $ (111)
v3.25.1
Consolidated Statements of Equity - USD ($)
$ in Millions
Total
Retained Earnings and Additional Paid-in Capital
Accumulated Other Comprehensive Income (AOCI)
Common Stock Issued Amount
Treasury Stock Amount
Beginning balance at Dec. 31, 2023 $ 68,774 $ 153,843 $ (12,527) $ 3,120 $ (75,662)
Net earnings 3,255 3,255      
Cash dividends paid (2,869) (2,869)      
Employee compensation and stock option plans 577 (851)     1,428
Repurchase of common stock (1,475)       (1,475)
Other (1)       (1)
Other comprehensive income (loss), net of tax 1,759   1,759    
Ending balance at Mar. 31, 2024 70,020 153,378 (10,768) 3,120 (75,710)
Beginning balance at Dec. 29, 2024 71,490 155,791 (11,741) 3,120 (75,680)
Net earnings 10,999 10,999      
Cash dividends paid (2,989) (2,989)      
Employee compensation and stock option plans 737 (1,166)     1,903
Repurchase of common stock (2,129)       (2,129)
Other comprehensive income (loss), net of tax 1   1    
Ending balance at Mar. 30, 2025 $ 78,109 $ 162,635 $ (11,740) $ 3,120 $ (75,906)
v3.25.1
Consolidated Statements of Equity (Parenthetical) - $ / shares
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Statement of Stockholders' Equity [Abstract]    
Cash dividends paid (in dollars per share) $ 1.24 $ 1.19
v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES    
Net earnings $ 10,999 $ 3,255
Adjustments to reconcile net earnings to cash flows from operating activities:    
Depreciation and amortization of property and intangibles 1,772 1,815
Stock based compensation 288 302
Asset write-downs 30 185
Charges for purchase of in-process research and development assets 16 0
Net gain on sale of assets/businesses (75) 0
Deferred tax provision 2,172 (1,562)
Credit losses and accounts receivable allowances (4) 0
Changes in assets and liabilities, net of effects from acquisitions and divestitures:    
Increase in accounts receivable (926) (279)
Increase in inventories (146) (348)
Decrease in accounts payable and accrued liabilities (2,126) (2,483)
(Increase)/Decrease in other current and non-current assets (1,317) 3,199
Decrease in other current and non-current liabilities (6,509) (427)
Net cash flows from operating activities 4,174 3,657
Cash flows from investing activities    
Additions to property, plant and equipment (795) (807)
Proceeds from the disposal of assets/businesses, net (Note 10) 279 210
Acquisitions, net of cash acquired (Note 10) 0 (1,811)
Acquired in-process research and development assets (Note 10) (14) 0
Purchases of investments (251) (630)
Sales of investments 218 979
Credit support agreements activity, net 296 1,600
Other (including capitalized licenses and milestones) (30) (5)
Net cash used by investing activities (297) (464)
Cash flows from financing activities    
Dividends to shareholders (2,989) (2,869)
Repurchase of common stock (2,127) (1,475)
Proceeds from short-term debt, net 8,784 5,263
Repayment of short-term debt, net (2,120) (890)
Proceeds from long-term debt, net of issuance costs 9,138 2
Repayment of long-term debt (751) (1)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 450 195
Credit support agreements activity, net (3) 228
Other 40 93
Net cash from financing activities 10,422 546
Effect of exchange rate changes on cash and cash equivalents 70 (125)
Increase in cash and cash equivalents 14,369 3,614
Cash and Cash equivalents beginning of period 24,105 21,859
Cash and cash equivalents, end of period 38,474 25,473
Acquisitions (Note 10)    
Fair value of assets acquired 0 1,899
Fair value of liabilities assumed 0 (88)
Net cash paid for acquisitions $ 0 $ 1,811
v3.25.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 30, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.
Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
New accounting standards
The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024.
Recently adopted accounting standards
There were no new material accounting standards adopted in the fiscal first quarter of 2025.
Recently issued accounting standards
There were no new material accounting standards issued in the fiscal first quarter of 2025.
Supplier finance program obligations
The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to participate in the program.
Confirmed obligations under the program as of March 30, 2025, and December 29, 2024, were $0.6 billion and $0.8 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.
v3.25.1
Inventories
 3 Months Ended
Mar. 30, 2025
Inventory Disclosure [Abstract]  
Inventories Inventories
(Dollars in Millions)March 30, 2025December 29, 2024
Raw materials and supplies$2,3712,337
Goods in process3,2032,815
Finished goods7,0857,292
Total inventories$12,65912,444
v3.25.1
Intangible Assets and Goodwill
 3 Months Ended
Mar. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible assets and goodwill
Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.
(Dollars in Millions)March 30, 2025December 29, 2024
Intangible assets with definite lives:  
Patents and trademarks — gross$45,59144,695
Less accumulated amortization(27,748)(26,124)
Patents and trademarks — net$17,84318,571
Customer relationships and other intangibles — gross20,49320,310
Less accumulated amortization(13,882)(13,544)
Customer relationships and other intangibles — net(1)
$6,6116,766
Intangible assets with indefinite lives:  
Purchased in-process research and development12,30112,281
Total intangible assets — net$36,75537,618
(1)The majority is comprised of customer relationships
Goodwill as of March 30, 2025 was allocated by segment of business as follows:
(Dollars in Millions)
Innovative
Medicine
MedTechTotal
Goodwill at December 29, 2024
$10,69233,50844,200
Goodwill, related to acquisitions———
Goodwill, related to divestitures—(29)(29)
Currency translation/Other21582297
Goodwill at March 30, 2025
$10,90733,56144,468
    
The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $1.1 billion for both of the fiscal first quarters ended March 30, 2025 and March 31, 2024.
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20252026202720282029
$4,0003,4002,8002,2002,200
See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.
v3.25.1
Fair Value Measurements
 3 Months Ended
Mar. 30, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair value measurements
The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.
Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.
The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 30, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $1.9 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 30, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.2 billion, $40.0 billion and $9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.1 billion, $40.5 billion and $9.0 billion, respectively.
All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.
Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.
The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.
As of March 30, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $1.2 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended March 30, 2025 and March 31, 2024, net of tax:
March 30, 2025March 31, 2024
(Dollars in Millions)Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
    Hedged items$———188————8—
    Derivatives designated as hedging instruments———(188)————(8)—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———49————34—
   Amount of gain or (loss) recognized in AOCI———49————34—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income (1)101——11654—(2)
   Amount of gain or (loss) recognized in AOCI 3105(36)—(11)(3)(19)22—4
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———83————49—
   Amount of gain or (loss) recognized in AOCI$———566————(205)—
As of March 30, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is includedCarrying Amount of the Hedged Liability
Cumulative Amount of Fair Value
Hedging Gain/ (Loss) Included in the
Carrying Amount of the Hedged Liability
(Dollars in Millions)March 30, 2025December 29, 2024March 30, 2025December 29, 2024
Long-term Debt$8,1477,935(889)(1,132)

The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2025 and 2024:
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)Location of
Gain /(Loss)
Recognized in
Income on Derivative		Fiscal First Quarter Ended
Derivatives Not Designated as Hedging InstrumentsMarch 30, 2025March 31, 2024
Foreign Exchange ContractsOther (income) expense$6225

The following table is the effect of net investment hedges for the fiscal first quarters ended in 2025 and 2024:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)March 30, 2025March 31, 2024March 30, 2025March 31, 2024
Debt$(316)84Interest (income) expense——
Cross Currency interest rate swaps$840728Interest (income) expense——
The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
The following table is a summary of the activity related to equity investments:
December 29, 2024March 30, 2025
(Dollars in Millions)Carrying Value
Changes in Fair Value Reflected in Net Income (1)
(Sales)/ Purchases/Other (2)
Carrying ValueNon Current Other Assets
Equity Investments with readily determinable value$451(36)56471471
Equity Investments without readily determinable value$773(27)41787787
(1)Recorded in Other (income)/expense, net
(2)Other includes impact of currency

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.
The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.
The following three levels of inputs are used to measure fair value:
Level 1 — Quoted prices in active markets for identical assets and liabilities.
Level 2 — Significant other observable inputs.
Level 3 — Significant unobservable inputs.
The Company’s significant financial assets and liabilities measured at fair value as of March 30, 2025 and December 29, 2024 were as follows:
 March 30, 2025December 29, 2024
(Dollars in Millions)Level 1Level 2Level 3Total
Total(1)
Derivatives designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $—389—389660
Interest rate contracts(2)
—1,285—1,2851,484
Total —1,674—1,6742,144
Liabilities:     
Forward foreign exchange contracts —345—345794
Interest rate contracts(2)
—3,415—3,4153,753
Total —3,760—3,7604,547
Derivatives not designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts —37—3750
Liabilities:     
Forward foreign exchange contracts —25—2517
Other Investments:
Equity investments(3)
471——471451
Debt securities(4)
—8,448—8,4487,216
Other Liabilities:
Contingent consideration(5)
$——1,2311,2311,217
Gross to Net Derivative ReconciliationMarch 30, 2025December 29, 2024
(Dollars in Millions)
Total Gross Assets$1,7112,194
Credit Support Agreement (CSA)(1,700)(2,172)
Total Net Asset1122
Total Gross Liabilities3,7854,564
Credit Support Agreement (CSA)(3,648)(4,412)
Total Net Liabilities$137152
Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended March 30, 2025 and March 31, 2024 is as follows:
March 30, 2025March 31, 2024
(Dollars in Millions)
Beginning Balance$1,2171,092
Changes in estimated fair value(6)
1422
Additions——
Payments——
Ending Balance$1,2311,114
(1)2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $451 million, which are classified as Level 1 and contingent consideration of $1,217 million, classified as Level 3.
(2)Includes cross currency interest rate swaps and interest rate swaps.
(3)Classified as non-current other assets.
(4)Classified within cash equivalents and current marketable securities.
(5)Includes $1,181 million and $1,217 million classified as non-current other liabilities as of March 30, 2025 and December 29, 2024, respectively. Includes $50 million classified as current liabilities as of March 30, 2025.
(6)Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
The Company's cash, cash equivalents and current marketable securities as of March 30, 2025 comprised:
(Dollars in Millions)
Carrying
Amount
Unrealized Gain
Estimated
Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash$3,059—3,0593,059—
U.S. Gov't securities—————
Non-U.S. sovereign securities—————
U.S. reverse repurchase agreements6,938—6,9386,938—
Corporate debt securities(1)
—————
Money market funds19,690—19,69019,690—
Time deposits(1)
646—646646—
   Subtotal 30,333—30,33330,333—
U.S. Gov’t securities8,03218,0338,02013
U.S. Gov’t Agencies—————
Other sovereign securities180—18064116
Corporate debt securities235—23557178
   Subtotal available for sale debt(2)
$8,44718,4488,141307
Total cash, cash equivalents and current marketable securities$38,780138,78138,474307
(1)Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
As of the fiscal year ended December 29, 2024, the carrying amount of cash, cash equivalents and current marketable securities was approximately the same as the estimated fair value.
Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
The contractual maturities of the available for sale securities as of March 30, 2025 are as follows:
(Dollars in Millions)Cost BasisFair Value
Due within one year$8,4288,429
Due after one year through five years1919
Due after five years through ten years——
Total debt securities$8,4478,448
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 30, 2025:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Financial Liabilities  
Current Debt$13,89713,855
Non-Current Debt  
2.95% Notes due 2027
950980
0.95% Notes due 2027
1,4791,395
4.50% Notes due 2027(1)
749757
2.90% Notes due 2028
1,4981,452
1.150% Notes due 2028 (750MM Euro 1.0784)
806772
4.55% Notes due 2028(1)
748758
4.80% Notes due 2029
1,1461,175
6.95% Notes due 2029
299334
2.70% Notes due 2029 (600MM Euro 1.0784)(1)
646648
1.30% Notes due 2030
1,6721,499
4.70% Notes due 2030(1)
9951,017
4.90% Notes due 2031
1,1461,178
3.20% Notes due 2032 (700MM Euro 1.0784)
752762
4.85% Notes due 2032(1)
1,2421,268
4.95% Notes due 2033
499514
4.375% Notes due 2033
854838
3.050% Notes due 2033 ( 700MM Euro 1.0784)(1)
752749
4.95% Notes due 2034

846870
1.650% Notes due 2035 (1.5B Euro 1.0784)
1,6071,393
5.00% Notes due 2035(1)
1,243 1,270 
3.35% Notes due 2036 (800MM Euro 1.0784)

858849
3.587% Notes due 2036
897894
5.95% Notes due 2037
9941,094
3.625% Notes due 2037
1,3871,333
3.350% Notes due 2037 (1.0B Euro 1.0784)(1)
1,0751,058
3.40% Notes due 2038
993855
5.85% Notes due 2038
697760
4.50% Notes due 2040
542524
2.10% Notes due 2040
874689
4.85% Notes due 2041
298293
4.50% Notes due 2043
496464
3.55% Notes due 2044 (1.0B Euro 1.0784)
1,0681,037
3.60% Notes due 2045 (700MM Euro 1.0784)(1)
749723
3.73% Notes due 2046
1,9791,604
3.75% Notes due 2047
852802
3.50% Notes due 2048
744569
2.25% Notes due 2050
837582
5.25% Notes due 2054

843850
3.70% Notes due 2055 (1.0B Euro 1.0784)(1)
1,0721,020
2.45% Notes due 2060
1,088694
Other8383
Total Non-Current Debt$38,35536,406
(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.
The weighted average effective interest rate on non-current debt is 3.58%.
The excess of the carrying value over the estimated fair value of debt was $2.0 billion at December 29, 2024.
Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.
The current debt balance as of March 30, 2025, includes $10.9 billion of commercial paper which has a weighted average interest rate of 4.28% and a weighted average maturity of approximately two months.
v3.25.1
Income Taxes
 3 Months Ended
Mar. 30, 2025
Income Tax Disclosure [Abstract]  
Income Taxes Income taxes
The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were 19.3% and 12.4%, respectively. The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal first quarter of 2025 the Company reversed approximately $7.0 billion, a significant portion of the previously accrued talc reserve versus a charge of $2.7 billion recorded in the fiscal first quarter of 2024 for the talc settlement proposal. Both charges were recorded at an effective U.S. federal and state tax rate of approximately 22% (for further information see Note 11 to the Consolidated Financial Statements).
As of March 30, 2025, the Company had approximately $2.1 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020.
In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States.
v3.25.1
Pensions and Other Benefit Plans
 3 Months Ended
Mar. 30, 2025
Retirement Benefits [Abstract]  
Pensions and Other Benefit Plans Pensions and other benefit plans
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal First Quarter Ended
 Retirement PlansOther Benefit Plans
(Dollars in Millions)March 30, 2025March 31, 2024March 30, 2025March 31, 2024
Service cost$2142247269
Interest cost3513525452
Expected return on plan assets(587)(642)(2)(2)
Amortization of prior service cost/(credit)
(46)(46)——
Recognized actuarial (gains)/losses83431613
Net periodic benefit cost/(credit)$15(69)140132
The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.
Company contributions
For the fiscal three months ended March 30, 2025, the Company contributed $34 million and $4 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.
v3.25.1
Accumulated Other Comprehensive Income
 3 Months Ended
Mar. 30, 2025
Equity [Abstract]  
Accumulated Other Comprehensive Income Accumulated other comprehensive income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions)
Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit
Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income/(Loss)
December 29, 2024$(8,441)1(1,551)(1,750)(11,741)
Net change(575)0425341
March 30, 2025(9,016)1(1,509)(1,216)(11,740)
Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.
Details on reclassifications out of Accumulated Other Comprehensive Income:
Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.
Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.
v3.25.1
Earnings Per Share
 3 Months Ended
Mar. 30, 2025
Earnings Per Share [Abstract]  
Earnings Per Share Earnings per share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
 Fiscal First Quarter Ended
(Shares in Millions)March 30, 2025March 31, 2024
Basic net earnings per share$4.571.35
Average shares outstanding — basic2,407.22,408.2
Potential shares exercisable under stock option plans69.087.6
Less: shares which could be repurchased under treasury stock method(52.4)(65.7)
Average shares outstanding — diluted2,423.82,430.1
Diluted net earnings per share$4.541.34
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 60.944.2
v3.25.1
Segments of Business and Geographic Areas
 3 Months Ended
Mar. 30, 2025
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas Segments of business and geographic areas
The Company is organized into two business segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
Sales by segment of business
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,0132,38326.4 %
International
2,6642,4309.6 
Worldwide
5,6784,81417.9 
CARVYKTI
U.S.
318140*
International
5116*
Worldwide
369157*
DARZALEX
U.S.
1,8291,46424.9 
International
1,4091,22814.7 
Worldwide
3,2372,69220.3 
ERLEADA
U.S.
2922852.5 
International
47940418.5 
Worldwide
77168911.9 
IMBRUVICA
U.S.
235265(11.5)
International
474518(8.5)
Worldwide
709784(9.5)
RYBREVANT/ LAZCLUZE(1)
U.S.
11336*
International
2811*
Worldwide
14147*
TALVEY(1)
U.S.
68 50 35.2 
International
18 8 *
Worldwide
86 58 48.4 
TECVAYLI
U.S.
1051014.9 
International
463338.8 
Worldwide
15113313.3 
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
ZYTIGA / abiraterone acetate
U.S.
79(24.3)
International
118172(31.3)
Worldwide
125181(30.9)
OTHER ONCOLOGY
U.S.
473342.9 
International
42414.6 
Worldwide
897321.7 
Immunology
U.S.
2,1962,453(10.5)
International
1,5101,794(15.8)
Worldwide
3,7074,247(12.7)
REMICADE
U.S.
31426618.1 
U.S. Exports
1027(64.2)
International
1431411.3 
Worldwide
4674347.5 
SIMPONI / SIMPONI ARIA
U.S.
29225414.8 
International
36629922.4 
Worldwide
65955418.9 
STELARA
U.S.
9811,396(29.8)
International
6441,055(38.9)
Worldwide
1,6252,451(33.7)
TREMFYA
U.S.
59950917.6 
International
35629919.2 
Worldwide
95680818.2 
OTHER IMMUNOLOGY
U.S.
10*
International
00— 
Worldwide
10*
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
Neuroscience
U.S.
9681,054(8.1)
International
679749(9.3)
Worldwide
1,6471,803(8.6)
CONCERTA / methylphenidate
U.S.
3841(7.4)
International
110136(18.9)
Worldwide
148177(16.3)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
625765(18.2)
International
277292(4.9)
Worldwide
9031,056(14.5)
SPRAVATO
U.S.
27619145.0 
International
433425.0 
Worldwide
32022541.9 
OTHER NEUROSCIENCE
U.S.
2858(50.6)
International
248287(13.4)
Worldwide
277345(19.6)
Pulmonary Hypertension
U.S.
744766(2.9)
International
281283(0.6)
Worldwide
1,0251,049(2.3)
OPSUMIT/OPSYNVI(2)
U.S.3633562.1 
International159169(6.0)
Worldwide522524(0.5)
UPTRAVI
U.S.365392(6.9)
International867613.4 
Worldwide 451468(3.6)
OTHER PULMONARY HYPERTENSION(2)
U.S.
1518(12.7)
International3739(4.6)
Worldwide 5256(7.2)
Infectious Diseases
U.S.
315324(2.8)
International
487497(1.9)
Worldwide
802821(2.2)
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
EDURANT / rilpivirine
U.S.
88(1.3)
International
35031511.0 
Worldwide
35832310.7 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
305314(2.9)
International
98104(6.2)
Worldwide
403418(3.7)
OTHER INFECTIOUS DISEASES(3)
U.S.
227.7 
International
3977(48.8)
Worldwide
4178(47.6)
Cardiovascular / Metabolism / Other
U.S.85563135.4 
International158197(19.7)
Worldwide1,01382922.3 
XARELTO
U.S.69051833.3 
International——— 
Worldwide69051833.3 
OTHER
U.S.16511445.0 
International158197(19.7)
Worldwide3233113.9 
TOTAL INNOVATIVE MEDICINE  
U.S.8,0927,6126.3 
International5,7815,950(2.9)
Worldwide13,87313,5622.3 
MEDTECH
Cardiovascular
U.S.1,2611,02523.0 
International8427817.8 
Worldwide2,1031,80616.4 
ELECTROPHYSIOLOGY
U.S.684692(1.1)
International638652(2.0)
Worldwide1,3231,344(1.6)
ABIOMED
U.S.33930311.9 
International816719.7 
Worldwide42037113.3 
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
SHOCKWAVE
U.S.206—*
International52—*
Worldwide258—*
OTHER CARDIOVASCULAR
U.S.32307.1 
International726215.1 
Worldwide1039212.5 
Orthopaedics
U.S.1,3841,448(4.4)
International857892(3.9)
Worldwide2,2412,340(4.2)
HIPS
U.S.263270(2.5)
International146152(4.0)
Worldwide409422(3.1)
KNEES
U.S.231242(4.3)
International158160(1.0)
Worldwide389401(3.0)
TRAUMA
U.S.502504(0.5)
International2702613.7 
Worldwide7727650.9 
SPINE, SPORTS & OTHER
U.S.388432(10.2)
International283320(11.6)
Worldwide671752(10.8)
Surgery
U.S.1,0029871.5 
International1,3941,429(2.5)
Worldwide2,3962,416(0.8)
ADVANCED
U.S.4574462.7 
International616641(4.0)
Worldwide1,0731,087(1.2)
GENERAL
U.S.5445420.5 
International778788(1.2)
Worldwide1,3231,330(0.5)
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
Vision
U.S.5665473.4 
International7137100.4 
Worldwide1,2791,2581.7 
CONTACT LENSES / OTHER
U.S.4524383.1 
International467472(1.1)
Worldwide9199101.0 
SURGICAL
U.S.1141104.3 
International2462383.4 
Worldwide3613483.7 
TOTAL MEDTECH  
U.S.4,2134,0085.1 
International3,8073,813(0.2)
Worldwide8,0207,8212.5 
WORLDWIDE   
U.S.12,30511,6205.9 
International9,5889,763(1.8)
Worldwide$21,89321,3832.4 %
*    Percentage greater than 100% or not meaningful
(1) Previously in Other Oncology
(2) Opsynvi was previously in Other Pulmonary Hypertension
(3) Includes the Covid-19 Vaccine in 2024
Segment income before tax
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$13,8738,02013,5627,821
Cost of products sold4,0203,3263,3703,120
Selling, marketing and administrative2,2612,6562,4382,582
Research and development expense2,5486772,896646
Other segment items (3)
(166)(60)(111)(47)
Segment income before tax$5,2101,4216,6314,9691,5206,489
(Income) Expense not allocated to segments (4)
(7,000)2,775
Earnings before provision for taxes on income$13,631$3,714
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.6 billion and $0.7 billion in the fiscal first quarter of 2025 and 2024, respectively.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2024. Refer to Note 12 for additional details.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal first quarter of 2025 and 2024, respectively.
•Acquisition and integration related expense of $0.1 billion in both the fiscal first quarters of 2025 and 2024 primarily driven by the Shockwave acquisition in fiscal 2025 and Abiomed in fiscal 2024.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2025.
(3)    Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.

Identifiable Assets
(Dollars in Millions)March 30, 2025December 29, 2024
Innovative Medicine$58,72757,070
MedTech85,11184,322
Total143,838141,392
General corporate (1)
49,83338,712
Worldwide total$193,671180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)March 30, 2025March 31, 2024March 30, 2025March 31, 2024
Innovative Medicine$276232$8841,011
MedTech480493836746
Segments total7567251,7201,757
General corporate39825258
Worldwide total$795807$1,7721,815

Sales by geographic area
 Fiscal First Quarter Ended
(Dollars in Millions)March 30, 2025March 31, 2024Percent
Change
United States$12,30511,6205.9 %
Europe5,1105,163(1.0)
Western Hemisphere, excluding U.S.1,1671,194(2.3)
Asia-Pacific, Africa3,3113,406(2.8)
Total$21,89321,3832.4 %
v3.25.1
Acquisitions and Divestitures
 3 Months Ended
Mar. 30, 2025
Business Combinations [Abstract]  
Acquisitions and Divestitures Acquisitions and divestitures
Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. The Company acquired all the outstanding shares of Intra-Cellular’s common stock for $132.00 per share in cash for a total equity value of approximately $14.6 billion. The Company funded the transaction through a combination of cash on hand and proceeds from the issuance of debt in the fiscal first quarter of 2025. See Note 4 to the Consolidated Financial Statements for additional details.

The Company is in the process of determining the preliminary fair value of assets acquired which will primarily be comprised of amortizable intangible assets and in-process research and development assets associated with CAPLYTA, liabilities assumed and total consideration transferred. This transaction will be accounted for as a business combination and the results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.

Business combinations

In the fiscal first quarter of 2025, there were no material business combinations.

On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $0.9 billion, goodwill for $0.3 billion, and liabilities assumed of $0.3 billion, including $0.1 billion of contingent consideration. The goodwill is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period.

On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $11.5 billion, net of cash acquired. The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $14.4 billion primarily amortizable intangible assets of $5.3 billion, purchased IPR&D of $0.6 billion, goodwill for $7.6 billion, $0.5 billion of inventory and $0.4 billion of other assets, and liabilities assumed of $2.9 billion. The goodwill is not expected to be deductible for tax purposes. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax for the fiscal first quarter of 2025 were $0.1 billion, primarily related to the fair value of the inventory step-up and were recorded in Cost of products sold.

On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $1.9 billion, goodwill for $0.3 billion and liabilities assumed of $0.5 billion, which includes deferred taxes of $0.4 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal first quarter of 2025 were not material.

Asset acquisitions

In the fiscal first quarters of 2025 and 2024, there were no material asset acquisitions.
Divestitures
In the fiscal first quarter of 2025, there were no material divestitures.
In the fiscal first quarter of 2024, the Company completed the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2 billion in proceeds.
v3.25.1
Legal Proceedings
 3 Months Ended
Mar. 30, 2025
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings Legal proceedings
Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 30, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.
Matters concerning talc
A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder.
In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases.
In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers’ use of talc contained in JOHNSON’S Baby Powder and JOHNSON’S Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter.
In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter.
Forty-two states and the District of Columbia commenced a joint investigation into the Company’s marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized.
In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old
JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities).
In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.
The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court’s ruling and remanded to the Bankruptcy Court to dismiss the LTL Bankruptcy Case.
In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).
Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Court’s extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed.
Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy Case followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy Case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTL’s petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL 2 Bankruptcy Case.
In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual “prepackaged” bankruptcy case, as “strongly encouraged” by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company’s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).
Following the dismissal of the LTL 2 Bankruptcy Case, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings were stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.
In May 2024, the Company commenced a three-month solicitation period of its proposed consensual “prepackaged” Chapter 11 bankruptcy plan (the Proposed Plan) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.0 billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constitute 99.75% of pending lawsuits against the Company relating to its talc powder products.
In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.
In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities.
Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024 (the Stay Order). The Stay Order was extended in October 2024, December 2024, and on March 13, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation began on February 18, 2025 and concluded on February 28, 2025.
To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $11.6 billion (or nominal value of approximately $13.5 billion). On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case and, as a result, the Company reversed substantially all, or approximately $7 billion, from amounts previously reserved for the bankruptcy resolution. Further, as a result of the dismissal, the Stay Order was dissolved. On April 1, 2025, the Company provided notice to the MDL court that the pending Daubert motion should proceed.

While the Company has resolved 95% of the mesothelioma lawsuits filed to date, cases continue to be filed. Trials have commenced in various state courts. As of the first quarter 2025, the total present value of the reserve is approximately $4.2 billion, comprising previously executed settlement arrangements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.
In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.
In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust.
In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imerys’s and Cyprus’s alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imerys’s and Cyprus’s liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Company’s alleged indemnification obligations.
In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. Under the global settlement, the Company and its affiliates, on the one hand, and Imerys and Cyprus and their respective affiliates, on the other hand, release their claims against one another arising out of talc claims, including indemnification and contribution claims. In addition, under the settlement, the Company purchased the Imerys and Cyprus debtors' indemnification rights against the Company free and clear of all claims and interest (the Indemnity Buyback). In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including the mutual
releases, and Indemnity Buyback, were subject to certain conditions, which have since been satisfied. Accordingly, the mutual releases and Indemnity Buyback are now in effect.
Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied on January 13, 2025. The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals. The briefing of the Settlement Order appeal in the Delaware District Court is scheduled to be completed in April 2025.
On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective Chapter 11 plans had been accepted by each voting class of talc claimants. A joint confirmation hearing for the plans is scheduled for April 2025.
In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiff’s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court’s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.
Matters concerning opioids
Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.
To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.
In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $5.0 billion. Approximately 70% of the all-in settlement was paid by the end of fiscal first quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.
The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are under 35 remaining opioid cases against the Company and JPI in various state courts, 325 remaining cases in the Ohio multi-district litigation (MDL), and 3 additional cases in other federal courts.
In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024. The defendants including the Company filed appeals from the certification order in late February 2025.
Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.
Product liability
The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued
for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.
The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of March 30, 2025:
Product or product category
Number of plaintiffs
Body powders containing talc, primarily JOHNSON’S Baby Powder62,850
DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System50
PINNACLE Acetabular Cup System910
Pelvic meshes5,910
ETHICON PHYSIOMESH Flexible Composite Mesh140
ELMIRON1,140
The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.
MedTech
DePuy ASR XL Acetabular System and ASR Hip Resurfacing System
In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.
DePuy PINNACLE Acetabular Cup System
Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.
Ethicon Pelvic Mesh
Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally
filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products.
Ethicon Physiomesh
Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.
Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.
Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.
In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.
The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.
Innovative Medicine
ELMIRON
Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.
Intellectual property
Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/
or validity of patents that relate to various products and allegations that certain of the Company’s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.
Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)
The Company’s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book). In each of these lawsuits, the Company’s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company’s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company’s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.
The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.
XARELTO
Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy’s Laboratories, Inc.; Dr. Reddy’s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.
U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument is scheduled to be heard in May 2025.
INVEGA SUSTENNA
Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.
Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.
INVEGA TRINZA
Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan’s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision.
SYMTUZA
Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. In February 2025, Janssen entered into confidential settlement agreements with all defendants, and consent judgments dismissing the cases were entered.
ERLEADA
In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz’s filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the ’345 patent), 2,875,767 (the ’767 patent), 2,885,415 (the ’415 patent), and 3,128,331 (the ’331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.
SPRAVATO
Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.
INVOKANA
Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.
CAPLYTA
Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddy’s Laboratories Inc., Dr. Reddy’s Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Sandoz Inc., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In January 2025, Intra-Cellular entered into a confidential settlement agreement with Sandoz Inc. and the case was dismissed.
MedTech
In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (’100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for
infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the ’100 patent. In September 2021, the court granted Abiomed’s motion for summary judgment of non-infringement of the ’100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.

In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (’238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (’783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the ’238 patent, vacated the judgment regarding the ’783 patent, and remanded the case to the District Court for further proceedings on the ’783 patent.

Government proceedings
Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.
MedTech
In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.
Innovative Medicine
In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssen’s motions and the Company is appealing the verdict and judgments.
In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.
General litigation
The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company’s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation at such sites.
In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical
device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.
In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company’s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants’ motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint.
MedTech
In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon’s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants’ motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.
In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025.
Innovative Medicine
In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen’s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.
In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.
In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.
In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.
v3.25.1
Restructuring
 3 Months Ended
Mar. 30, 2025
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal first quarter of 2025 primarily included costs related to asset impairments and market and product exits. The pre-tax restructuring expense in the fiscal first quarter of 2024 primarily included costs related to market and product exits. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and is expected to be completed by the end of fiscal year 2025.
The following table summarizes the restructuring expenses for 2025 and 2024:
(Pre-tax Dollars in Millions)Q1 2025Q1 2024
MedTech Segment(1)
$5527
Innovative Medicine Segment(2)
0144
Total Programs$55171
(1)Includes $17 million in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2025. Included $20 million in Restructuring and $7 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal first quarter of 2024.
(2)Included in Restructuring on the Consolidated Statement of Earnings in the fiscal first quarter of 2024. This program was completed in the fiscal fourth quarter of 2024.
Restructuring reserves as of March 30, 2025 and December 29, 2024 were insignificant.
v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net earnings $ 10,999 $ 3,255
v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 30, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 30, 2025
Accounting Policies [Abstract]  
New and Recently Adopted Accounting Standards
New accounting standards
The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024.
Recently adopted accounting standards
There were no new material accounting standards adopted in the fiscal first quarter of 2025.
Recently issued accounting standards
There were no new material accounting standards issued in the fiscal first quarter of 2025.
Cash and Cash Equivalents
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
v3.25.1
Inventories (Tables)
 3 Months Ended
Mar. 30, 2025
Inventory Disclosure [Abstract]  
Summary of Inventories
(Dollars in Millions)March 30, 2025December 29, 2024
Raw materials and supplies$2,3712,337
Goods in process3,2032,815
Finished goods7,0857,292
Total inventories$12,65912,444
v3.25.1
Intangible Assets and Goodwill (Tables)
 3 Months Ended
Mar. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
(Dollars in Millions)March 30, 2025December 29, 2024
Intangible assets with definite lives:  
Patents and trademarks — gross$45,59144,695
Less accumulated amortization(27,748)(26,124)
Patents and trademarks — net$17,84318,571
Customer relationships and other intangibles — gross20,49320,310
Less accumulated amortization(13,882)(13,544)
Customer relationships and other intangibles — net(1)
$6,6116,766
Intangible assets with indefinite lives:  
Purchased in-process research and development12,30112,281
Total intangible assets — net$36,75537,618
(1)The majority is comprised of customer relationships
Goodwill
Goodwill as of March 30, 2025 was allocated by segment of business as follows:
(Dollars in Millions)
Innovative
Medicine
MedTechTotal
Goodwill at December 29, 2024
$10,69233,50844,200
Goodwill, related to acquisitions———
Goodwill, related to divestitures—(29)(29)
Currency translation/Other21582297
Goodwill at March 30, 2025
$10,90733,56144,468
Intangible Asset Amortization Expense
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20252026202720282029
$4,0003,4002,8002,2002,200
v3.25.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 30, 2025
Fair Value Disclosures [Abstract]  
Summary of Derivative Activity
The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended March 30, 2025 and March 31, 2024, net of tax:
March 30, 2025March 31, 2024
(Dollars in Millions)Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
    Hedged items$———188————8—
    Derivatives designated as hedging instruments———(188)————(8)—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———49————34—
   Amount of gain or (loss) recognized in AOCI———49————34—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income (1)101——11654—(2)
   Amount of gain or (loss) recognized in AOCI 3105(36)—(11)(3)(19)22—4
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———83————49—
   Amount of gain or (loss) recognized in AOCI$———566————(205)—
The following table is the effect of net investment hedges for the fiscal first quarters ended in 2025 and 2024:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)March 30, 2025March 31, 2024March 30, 2025March 31, 2024
Debt$(316)84Interest (income) expense——
Cross Currency interest rate swaps$840728Interest (income) expense——
Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet
As of March 30, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is includedCarrying Amount of the Hedged Liability
Cumulative Amount of Fair Value
Hedging Gain/ (Loss) Included in the
Carrying Amount of the Hedged Liability
(Dollars in Millions)March 30, 2025December 29, 2024March 30, 2025December 29, 2024
Long-term Debt$8,1477,935(889)(1,132)
Schedule of Effect of Derivatives not Designated as Hedging Instruments
The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2025 and 2024:
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)Location of
Gain /(Loss)
Recognized in
Income on Derivative		Fiscal First Quarter Ended
Derivatives Not Designated as Hedging InstrumentsMarch 30, 2025March 31, 2024
Foreign Exchange ContractsOther (income) expense$6225
Summary of Activity Related to Equity Investments
The following table is a summary of the activity related to equity investments:
December 29, 2024March 30, 2025
(Dollars in Millions)Carrying Value
Changes in Fair Value Reflected in Net Income (1)
(Sales)/ Purchases/Other (2)
Carrying ValueNon Current Other Assets
Equity Investments with readily determinable value$451(36)56471471
Equity Investments without readily determinable value$773(27)41787787
(1)Recorded in Other (income)/expense, net
(2)Other includes impact of currency
Financial Assets and Liabilities at Fair Value
The Company’s significant financial assets and liabilities measured at fair value as of March 30, 2025 and December 29, 2024 were as follows:
 March 30, 2025December 29, 2024
(Dollars in Millions)Level 1Level 2Level 3Total
Total(1)
Derivatives designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $—389—389660
Interest rate contracts(2)
—1,285—1,2851,484
Total —1,674—1,6742,144
Liabilities:     
Forward foreign exchange contracts —345—345794
Interest rate contracts(2)
—3,415—3,4153,753
Total —3,760—3,7604,547
Derivatives not designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts —37—3750
Liabilities:     
Forward foreign exchange contracts —25—2517
Other Investments:
Equity investments(3)
471——471451
Debt securities(4)
—8,448—8,4487,216
Other Liabilities:
Contingent consideration(5)
$——1,2311,2311,217
Gross to Net Derivative ReconciliationMarch 30, 2025December 29, 2024
(Dollars in Millions)
Total Gross Assets$1,7112,194
Credit Support Agreement (CSA)(1,700)(2,172)
Total Net Asset1122
Total Gross Liabilities3,7854,564
Credit Support Agreement (CSA)(3,648)(4,412)
Total Net Liabilities$137152
Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended March 30, 2025 and March 31, 2024 is as follows:
March 30, 2025March 31, 2024
(Dollars in Millions)
Beginning Balance$1,2171,092
Changes in estimated fair value(6)
1422
Additions——
Payments——
Ending Balance$1,2311,114
(1)2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $451 million, which are classified as Level 1 and contingent consideration of $1,217 million, classified as Level 3.
(2)Includes cross currency interest rate swaps and interest rate swaps.
(3)Classified as non-current other assets.
(4)Classified within cash equivalents and current marketable securities.
(5)Includes $1,181 million and $1,217 million classified as non-current other liabilities as of March 30, 2025 and December 29, 2024, respectively. Includes $50 million classified as current liabilities as of March 30, 2025.
(6)Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
Marketable Securities
The Company's cash, cash equivalents and current marketable securities as of March 30, 2025 comprised:
(Dollars in Millions)
Carrying
Amount
Unrealized Gain
Estimated
Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash$3,059—3,0593,059—
U.S. Gov't securities—————
Non-U.S. sovereign securities—————
U.S. reverse repurchase agreements6,938—6,9386,938—
Corporate debt securities(1)
—————
Money market funds19,690—19,69019,690—
Time deposits(1)
646—646646—
   Subtotal 30,333—30,33330,333—
U.S. Gov’t securities8,03218,0338,02013
U.S. Gov’t Agencies—————
Other sovereign securities180—18064116
Corporate debt securities235—23557178
   Subtotal available for sale debt(2)
$8,44718,4488,141307
Total cash, cash equivalents and current marketable securities$38,780138,78138,474307
(1)Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities
The contractual maturities of the available for sale securities as of March 30, 2025 are as follows:
(Dollars in Millions)Cost BasisFair Value
Due within one year$8,4288,429
Due after one year through five years1919
Due after five years through ten years——
Total debt securities$8,4478,448
Financial Liabilities not Measured at Fair Value
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 30, 2025:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Financial Liabilities  
Current Debt$13,89713,855
Non-Current Debt  
2.95% Notes due 2027
950980
0.95% Notes due 2027
1,4791,395
4.50% Notes due 2027(1)
749757
2.90% Notes due 2028
1,4981,452
1.150% Notes due 2028 (750MM Euro 1.0784)
806772
4.55% Notes due 2028(1)
748758
4.80% Notes due 2029
1,1461,175
6.95% Notes due 2029
299334
2.70% Notes due 2029 (600MM Euro 1.0784)(1)
646648
1.30% Notes due 2030
1,6721,499
4.70% Notes due 2030(1)
9951,017
4.90% Notes due 2031
1,1461,178
3.20% Notes due 2032 (700MM Euro 1.0784)
752762
4.85% Notes due 2032(1)
1,2421,268
4.95% Notes due 2033
499514
4.375% Notes due 2033
854838
3.050% Notes due 2033 ( 700MM Euro 1.0784)(1)
752749
4.95% Notes due 2034

846870
1.650% Notes due 2035 (1.5B Euro 1.0784)
1,6071,393
5.00% Notes due 2035(1)
1,243 1,270 
3.35% Notes due 2036 (800MM Euro 1.0784)

858849
3.587% Notes due 2036
897894
5.95% Notes due 2037
9941,094
3.625% Notes due 2037
1,3871,333
3.350% Notes due 2037 (1.0B Euro 1.0784)(1)
1,0751,058
3.40% Notes due 2038
993855
5.85% Notes due 2038
697760
4.50% Notes due 2040
542524
2.10% Notes due 2040
874689
4.85% Notes due 2041
298293
4.50% Notes due 2043
496464
3.55% Notes due 2044 (1.0B Euro 1.0784)
1,0681,037
3.60% Notes due 2045 (700MM Euro 1.0784)(1)
749723
3.73% Notes due 2046
1,9791,604
3.75% Notes due 2047
852802
3.50% Notes due 2048
744569
2.25% Notes due 2050
837582
5.25% Notes due 2054

843850
3.70% Notes due 2055 (1.0B Euro 1.0784)(1)
1,0721,020
2.45% Notes due 2060
1,088694
Other8383
Total Non-Current Debt$38,35536,406
(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.
v3.25.1
Pensions and Other Benefit Plans (Tables)
 3 Months Ended
Mar. 30, 2025
Retirement Benefits [Abstract]  
Components of Net Periodic Benefit Cost
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal First Quarter Ended
 Retirement PlansOther Benefit Plans
(Dollars in Millions)March 30, 2025March 31, 2024March 30, 2025March 31, 2024
Service cost$2142247269
Interest cost3513525452
Expected return on plan assets(587)(642)(2)(2)
Amortization of prior service cost/(credit)
(46)(46)——
Recognized actuarial (gains)/losses83431613
Net periodic benefit cost/(credit)$15(69)140132
v3.25.1
Accumulated Other Comprehensive Income (Tables)
 3 Months Ended
Mar. 30, 2025
Equity [Abstract]  
Components of Accumulated Other Comprehensive Income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions)
Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit
Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income/(Loss)
December 29, 2024$(8,441)1(1,551)(1,750)(11,741)
Net change(575)0425341
March 30, 2025(9,016)1(1,509)(1,216)(11,740)
v3.25.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 30, 2025
Earnings Per Share [Abstract]  
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
 Fiscal First Quarter Ended
(Shares in Millions)March 30, 2025March 31, 2024
Basic net earnings per share$4.571.35
Average shares outstanding — basic2,407.22,408.2
Potential shares exercisable under stock option plans69.087.6
Less: shares which could be repurchased under treasury stock method(52.4)(65.7)
Average shares outstanding — diluted2,423.82,430.1
Diluted net earnings per share$4.541.34
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 60.944.2
v3.25.1
Segments of Business and Geographic Areas (Tables)
 3 Months Ended
Mar. 30, 2025
Segment Reporting [Abstract]  
Sales By Segment Of Business
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,0132,38326.4 %
International
2,6642,4309.6 
Worldwide
5,6784,81417.9 
CARVYKTI
U.S.
318140*
International
5116*
Worldwide
369157*
DARZALEX
U.S.
1,8291,46424.9 
International
1,4091,22814.7 
Worldwide
3,2372,69220.3 
ERLEADA
U.S.
2922852.5 
International
47940418.5 
Worldwide
77168911.9 
IMBRUVICA
U.S.
235265(11.5)
International
474518(8.5)
Worldwide
709784(9.5)
RYBREVANT/ LAZCLUZE(1)
U.S.
11336*
International
2811*
Worldwide
14147*
TALVEY(1)
U.S.
68 50 35.2 
International
18 8 *
Worldwide
86 58 48.4 
TECVAYLI
U.S.
1051014.9 
International
463338.8 
Worldwide
15113313.3 
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
ZYTIGA / abiraterone acetate
U.S.
79(24.3)
International
118172(31.3)
Worldwide
125181(30.9)
OTHER ONCOLOGY
U.S.
473342.9 
International
42414.6 
Worldwide
897321.7 
Immunology
U.S.
2,1962,453(10.5)
International
1,5101,794(15.8)
Worldwide
3,7074,247(12.7)
REMICADE
U.S.
31426618.1 
U.S. Exports
1027(64.2)
International
1431411.3 
Worldwide
4674347.5 
SIMPONI / SIMPONI ARIA
U.S.
29225414.8 
International
36629922.4 
Worldwide
65955418.9 
STELARA
U.S.
9811,396(29.8)
International
6441,055(38.9)
Worldwide
1,6252,451(33.7)
TREMFYA
U.S.
59950917.6 
International
35629919.2 
Worldwide
95680818.2 
OTHER IMMUNOLOGY
U.S.
10*
International
00— 
Worldwide
10*
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
Neuroscience
U.S.
9681,054(8.1)
International
679749(9.3)
Worldwide
1,6471,803(8.6)
CONCERTA / methylphenidate
U.S.
3841(7.4)
International
110136(18.9)
Worldwide
148177(16.3)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
625765(18.2)
International
277292(4.9)
Worldwide
9031,056(14.5)
SPRAVATO
U.S.
27619145.0 
International
433425.0 
Worldwide
32022541.9 
OTHER NEUROSCIENCE
U.S.
2858(50.6)
International
248287(13.4)
Worldwide
277345(19.6)
Pulmonary Hypertension
U.S.
744766(2.9)
International
281283(0.6)
Worldwide
1,0251,049(2.3)
OPSUMIT/OPSYNVI(2)
U.S.3633562.1 
International159169(6.0)
Worldwide522524(0.5)
UPTRAVI
U.S.365392(6.9)
International867613.4 
Worldwide 451468(3.6)
OTHER PULMONARY HYPERTENSION(2)
U.S.
1518(12.7)
International3739(4.6)
Worldwide 5256(7.2)
Infectious Diseases
U.S.
315324(2.8)
International
487497(1.9)
Worldwide
802821(2.2)
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
EDURANT / rilpivirine
U.S.
88(1.3)
International
35031511.0 
Worldwide
35832310.7 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
305314(2.9)
International
98104(6.2)
Worldwide
403418(3.7)
OTHER INFECTIOUS DISEASES(3)
U.S.
227.7 
International
3977(48.8)
Worldwide
4178(47.6)
Cardiovascular / Metabolism / Other
U.S.85563135.4 
International158197(19.7)
Worldwide1,01382922.3 
XARELTO
U.S.69051833.3 
International——— 
Worldwide69051833.3 
OTHER
U.S.16511445.0 
International158197(19.7)
Worldwide3233113.9 
TOTAL INNOVATIVE MEDICINE  
U.S.8,0927,6126.3 
International5,7815,950(2.9)
Worldwide13,87313,5622.3 
MEDTECH
Cardiovascular
U.S.1,2611,02523.0 
International8427817.8 
Worldwide2,1031,80616.4 
ELECTROPHYSIOLOGY
U.S.684692(1.1)
International638652(2.0)
Worldwide1,3231,344(1.6)
ABIOMED
U.S.33930311.9 
International816719.7 
Worldwide42037113.3 
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
SHOCKWAVE
U.S.206—*
International52—*
Worldwide258—*
OTHER CARDIOVASCULAR
U.S.32307.1 
International726215.1 
Worldwide1039212.5 
Orthopaedics
U.S.1,3841,448(4.4)
International857892(3.9)
Worldwide2,2412,340(4.2)
HIPS
U.S.263270(2.5)
International146152(4.0)
Worldwide409422(3.1)
KNEES
U.S.231242(4.3)
International158160(1.0)
Worldwide389401(3.0)
TRAUMA
U.S.502504(0.5)
International2702613.7 
Worldwide7727650.9 
SPINE, SPORTS & OTHER
U.S.388432(10.2)
International283320(11.6)
Worldwide671752(10.8)
Surgery
U.S.1,0029871.5 
International1,3941,429(2.5)
Worldwide2,3962,416(0.8)
ADVANCED
U.S.4574462.7 
International616641(4.0)
Worldwide1,0731,087(1.2)
GENERAL
U.S.5445420.5 
International778788(1.2)
Worldwide1,3231,330(0.5)
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
Vision
U.S.5665473.4 
International7137100.4 
Worldwide1,2791,2581.7 
CONTACT LENSES / OTHER
U.S.4524383.1 
International467472(1.1)
Worldwide9199101.0 
SURGICAL
U.S.1141104.3 
International2462383.4 
Worldwide3613483.7 
TOTAL MEDTECH  
U.S.4,2134,0085.1 
International3,8073,813(0.2)
Worldwide8,0207,8212.5 
WORLDWIDE   
U.S.12,30511,6205.9 
International9,5889,763(1.8)
Worldwide$21,89321,3832.4 %
*    Percentage greater than 100% or not meaningful
(1) Previously in Other Oncology
(2) Opsynvi was previously in Other Pulmonary Hypertension
(3) Includes the Covid-19 Vaccine in 2024
Operating Profit by Segment of Business
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$13,8738,02013,5627,821
Cost of products sold4,0203,3263,3703,120
Selling, marketing and administrative2,2612,6562,4382,582
Research and development expense2,5486772,896646
Other segment items (3)
(166)(60)(111)(47)
Segment income before tax$5,2101,4216,6314,9691,5206,489
(Income) Expense not allocated to segments (4)
(7,000)2,775
Earnings before provision for taxes on income$13,631$3,714
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.6 billion and $0.7 billion in the fiscal first quarter of 2025 and 2024, respectively.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2024. Refer to Note 12 for additional details.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal first quarter of 2025 and 2024, respectively.
•Acquisition and integration related expense of $0.1 billion in both the fiscal first quarters of 2025 and 2024 primarily driven by the Shockwave acquisition in fiscal 2025 and Abiomed in fiscal 2024.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2025.
(3)    Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.

Identifiable Assets
(Dollars in Millions)March 30, 2025December 29, 2024
Innovative Medicine$58,72757,070
MedTech85,11184,322
Total143,838141,392
General corporate (1)
49,83338,712
Worldwide total$193,671180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)March 30, 2025March 31, 2024March 30, 2025March 31, 2024
Innovative Medicine$276232$8841,011
MedTech480493836746
Segments total7567251,7201,757
General corporate39825258
Worldwide total$795807$1,7721,815
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
Sales by geographic area
 Fiscal First Quarter Ended
(Dollars in Millions)March 30, 2025March 31, 2024Percent
Change
United States$12,30511,6205.9 %
Europe5,1105,163(1.0)
Western Hemisphere, excluding U.S.1,1671,194(2.3)
Asia-Pacific, Africa3,3113,406(2.8)
Total$21,89321,3832.4 %
v3.25.1
Legal Proceedings (Tables)
 3 Months Ended
Mar. 30, 2025
Commitments and Contingencies Disclosure [Abstract]  
Summary Of Claims In Pending Lawsuits
Product or product category
Number of plaintiffs
Body powders containing talc, primarily JOHNSON’S Baby Powder62,850
DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System50
PINNACLE Acetabular Cup System910
Pelvic meshes5,910
ETHICON PHYSIOMESH Flexible Composite Mesh140
ELMIRON1,140
v3.25.1
Restructuring (Tables)
 3 Months Ended
Mar. 30, 2025
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Reserve
The following table summarizes the restructuring expenses for 2025 and 2024:
(Pre-tax Dollars in Millions)Q1 2025Q1 2024
MedTech Segment(1)
$5527
Innovative Medicine Segment(2)
0144
Total Programs$55171
(1)Includes $17 million in Restructuring, $8 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal first quarter of 2025. Included $20 million in Restructuring and $7 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal first quarter of 2024.
(2)Included in Restructuring on the Consolidated Statement of Earnings in the fiscal first quarter of 2024. This program was completed in the fiscal fourth quarter of 2024.
v3.25.1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Millions
Mar. 30, 2025
Dec. 29, 2024
Accounting Policies [Abstract]    
Supplier finance program, payment timing, period 90 days  
Supplier finance program, obligation $ 600 $ 800
v3.25.1
Inventories (Details) - USD ($)
$ in Millions
Mar. 30, 2025
Dec. 29, 2024
Inventory Disclosure [Abstract]    
Raw materials and supplies $ 2,371 $ 2,337
Goods in process 3,203 2,815
Finished goods 7,085 7,292
Total inventories $ 12,659 $ 12,444
v3.25.1
Intangible Assets and Goodwill (Details) - USD ($)
$ in Millions
Mar. 30, 2025
Dec. 29, 2024
Intangible assets with indefinite lives:    
Total intangible assets — net $ 36,755 $ 37,618
Purchased In-Process Research And Development    
Intangible assets with indefinite lives:    
Total intangible assets with indefinite lives 12,301 12,281
Patents And Trademarks    
Intangible assets with definite lives:    
Finite-lived intangible assets, gross 45,591 44,695
Less accumulated amortization (27,748) (26,124)
Finite-lived intangible assets, net 17,843 18,571
Customer relationships and other intangible assets    
Intangible assets with definite lives:    
Finite-lived intangible assets, gross 20,493 20,310
Less accumulated amortization (13,882) (13,544)
Finite-lived intangible assets, net $ 6,611 $ 6,766
v3.25.1
Intangible Assets and Goodwill - Goodwill By Segment (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2025
USD ($)
Goodwill [Roll Forward]  
Goodwill Beginning of Period $ 44,200
Goodwill, related to acquisitions 0
Goodwill, related to divestitures (29)
Currency translation/Other 297
Goodwill End of Period 44,468
Innovative Medicine  
Goodwill [Roll Forward]  
Goodwill Beginning of Period 10,692
Goodwill, related to acquisitions 0
Goodwill, related to divestitures 0
Currency translation/Other 215
Goodwill End of Period 10,907
MedTech  
Goodwill [Roll Forward]  
Goodwill Beginning of Period 33,508
Goodwill, related to acquisitions 0
Goodwill, related to divestitures (29)
Currency translation/Other 82
Goodwill End of Period $ 33,561
v3.25.1
Intangible Assets and Goodwill - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Finite-Lived Intangible Assets [Line Items]    
Amortization expense of amortizable intangible assets $ 1,100 $ 1,100
Patents And Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 12 years  
Customer relationships and other intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 19 years  
v3.25.1
Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
2025 $ 4,000  
2026 3,400  
2027 2,800  
2028 2,200  
2029 2,200  
Amortization of Intangible Assets $ 1,100 $ 1,100
v3.25.1
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 30, 2025
Dec. 29, 2024
Derivative [Line Items]    
Accumulated other comprehensive loss on derivatives, after tax $ (1,200)  
Hedging exposure 18 months  
Weighted average interest rate on non-current debt 3.58%  
Excess of carrying value over fair value of debt   $ 2,000
Current Debt $ 13,897 5,983
Commercial Paper    
Derivative [Line Items]    
Current Debt $ 10,900  
Weighted average interest rate 4.28%  
Term 2 months  
Forward foreign exchange contracts    
Derivative [Line Items]    
Collateral already posted, aggregate fair value $ 1,900  
Derivative, notional amount 45,200 45,100
Cross currency interest rate swaps    
Derivative [Line Items]    
Derivative, notional amount 40,000 40,500
Interest Rate Swap    
Derivative [Line Items]    
Derivative, notional amount $ 9,000 $ 9,000
v3.25.1
Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0
Cross currency interest rate swaps | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income 0 0
Fair Value Hedging | Interest Rate Swap | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Fair Value Hedging | Interest Rate Swap | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Fair Value Hedging | Interest Rate Swap | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 188 8
Amount of gain or (loss) recognized in AOCI (188) (8)
Fair Value Hedging | Interest Rate Swap | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Net Investment Hedging | Net Investment Hedging | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 49 34
Amount of gain or (loss) recognized in AOCI 49 34
Net Investment Hedging | Net Investment Hedging | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0
Amount of gain or (loss) recognized in AOCI 0 0
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 3 (3)
Amount of gain or (loss) reclassified from AOCI into income (1) 1
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 105 (19)
Amount of gain or (loss) reclassified from AOCI into income 10 165
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI (36) 22
Amount of gain or (loss) reclassified from AOCI into income 1 4
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI (11) 4
Amount of gain or (loss) reclassified from AOCI into income 0 (2)
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 566 (205)
Amount of gain or (loss) reclassified from AOCI into income 83 49
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) recognized in AOCI 0 0
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0
v3.25.1
Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($)
$ in Millions
Mar. 30, 2025
Dec. 29, 2024
Derivative [Line Items]    
Carrying Amount of the Hedged Liability $ 3,785 $ 4,564
Designated as Hedging Instrument    
Derivative [Line Items]    
Carrying Amount of the Hedged Liability 8,147 7,935
Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability $ (889) $ (1,132)
v3.25.1
Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Not Designated as Hedging Instrument | Forward foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain/(Loss) Recognized In Income on Derivative $ 62 $ 25
v3.25.1
Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Derivative Instruments, Gain (Loss) [Line Items]    
Gain/(Loss) Recognized In Accumulated OCI $ (316) $ 84
Other Income Expense Net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income 0 0
Cross Currency Interest Rate Contract    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain/(Loss) Recognized In Accumulated OCI 840 728
Cross Currency Interest Rate Contract | Other Income Expense Net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0
v3.25.1
Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Dec. 29, 2024
Equity Investment [Roll Forward]    
Non Current Other Assets $ 11,534 $ 11,414
Equity Securities | Equity Investments with readily determinable value    
Equity Investment [Roll Forward]    
Carrying value, beginning of period 451  
Equity, Fair Value Adjustment (36)  
Sales/ Purchases/Other 56  
Carrying value, end of period 471  
Non Current Other Assets 471  
Equity Securities | Equity Investments without readily determinable value    
Equity Investment [Roll Forward]    
Carrying value, beginning of period 773  
Equity, Fair Value Adjustment (27)  
Sales/ Purchases/Other 41  
Carrying value, end of period 787  
Non Current Other Assets $ 787  
v3.25.1
Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Dec. 29, 2024
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets $ 1,674    
Derivatives designated as hedging instruments : Liabilities 3,760    
Available-for-sale Securities, Equity Securities 471   $ 451
Available-for-sale Securities 8,448   7,216
Contingent consideration 1,231   1,217
Total Gross Assets 1,711   2,194
Credit Support Agreement (CSA) (1,700)   (2,172)
Total Net Asset 11   22
Total Gross Liabilities 3,785   4,564
Credit Support Agreement (CSA) (3,648)   (4,412)
Total Net Liabilities 137   152
Beginning Balance 1,217 $ 1,092  
Changes in estimated fair value(6) 14 22  
Additions 0 0  
Payments 0 0  
Ending Balance 1,231 $ 1,114  
Other Noncurrent Liabilities      
Financial assets and liabilities at fair value      
Contingent consideration 1,181   1,217
Other Current Liabilities      
Financial assets and liabilities at fair value      
Contingent consideration 50    
Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Available-for-sale Securities, Equity Securities 471   451
Available-for-sale Securities 0    
Contingent consideration 0    
Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 1,674   2,144
Derivatives designated as hedging instruments : Liabilities 3,760   4,547
Available-for-sale Securities, Equity Securities 0    
Available-for-sale Securities 8,448    
Contingent consideration 0    
Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Available-for-sale Securities, Equity Securities 0    
Available-for-sale Securities 0    
Contingent consideration 1,231   1,217
Interest Rate Contract      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 1,285    
Derivatives designated as hedging instruments : Liabilities 3,415    
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Interest Rate Contract | Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 1,285   1,484
Derivatives designated as hedging instruments : Liabilities 3,415   3,753
Interest Rate Contract | Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Forward foreign exchange contracts      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 389    
Derivatives designated as hedging instruments : Liabilities 345    
Derivatives not designated as hedging instruments : Assets 37    
Derivatives not designated as hedging instruments : Liabilities 25    
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Derivatives not designated as hedging instruments : Assets 0    
Derivatives not designated as hedging instruments : Liabilities 0    
Forward foreign exchange contracts | Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 389   660
Derivatives designated as hedging instruments : Liabilities 345   794
Derivatives not designated as hedging instruments : Assets 37   50
Derivatives not designated as hedging instruments : Liabilities 25   $ 17
Forward foreign exchange contracts | Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Derivatives not designated as hedging instruments : Assets 0    
Derivatives not designated as hedging instruments : Liabilities $ 0    
v3.25.1
Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 29, 2024
Mar. 30, 2025
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Estimated Fair Value $ 7,216 $ 8,448
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 24,105 38,474
Marketable securities 417 307
Total cash, cash equivalents and current marketable securities, Carrying Amount   38,780
Total cash, cash equivalents and current marketable securities, Unrealized Gain   1
Total cash, cash equivalents and current marketable securities, Estimated Fair Value   38,781
Excess of carrying value over fair value of debt $ 2,000  
Held-to-maturity Securities    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   30,333
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   30,333
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   30,333
Marketable securities   0
Held-to-maturity Securities | Cash    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   3,059
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   3,059
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   3,059
Marketable securities   0
Held-to-maturity Securities | U.S. Gov't securities    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   0
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   0
Marketable securities   0
Held-to-maturity Securities | Non-U.S. sovereign securities    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   0
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   0
Marketable securities   0
Held-to-maturity Securities | U.S. reverse repurchase agreements    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   6,938
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   6,938
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   6,938
Marketable securities   0
Held-to-maturity Securities | Corporate debt securities(1)    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   0
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   0
Marketable securities   0
Held-to-maturity Securities | Money market funds    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   19,690
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   19,690
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   19,690
Marketable securities   0
Held-to-maturity Securities | Time deposits(1)    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount   646
Held-to-maturity Securities, Unrecognized Gain   0
Held-to-maturity Securities - Estimated Fair Value   646
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   646
Marketable securities   0
Available-for-sale Securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   8,447
Available-for-sale Securities, Unrecognized Gain   1
Available-for-sale Securities - Estimated Fair Value   8,448
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   8,141
Marketable securities   307
Available-for-sale Securities | U.S. Gov’t securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   8,032
Available-for-sale Securities - Estimated Fair Value   8,033
Available-for-sale Securities | U.S. Gov’t Agencies    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   0
Available-for-sale Securities - Estimated Fair Value   0
Available-for-sale Securities | Non-U.S. sovereign securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   180
Available-for-sale Securities - Estimated Fair Value   180
Available-for-sale Securities | Corporate debt securities(1)    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount   235
Available-for-sale Securities - Estimated Fair Value   235
Available-for-sale Securities | Non-U.S. sovereign securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities, Unrecognized Gain   0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   64
Marketable securities   116
Available-for-sale Securities | Corporate debt securities(1)    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities, Unrecognized Gain   0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   57
Marketable securities   178
Available-for-sale Securities | U.S. Gov’t securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities, Unrecognized Gain   1
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   8,020
Marketable securities   13
Available-for-sale Securities | U.S. Gov’t Agencies    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities, Unrecognized Gain   0
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents   0
Marketable securities   $ 0
v3.25.1
Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)
$ in Millions
Mar. 30, 2025
USD ($)
Cost Basis  
Due within one year $ 8,428
Due after one year through five years 19
Due after five years through ten years 0
Total debt securities 8,447
Fair Value  
Due within one year 8,429
Due after one year through five years 19
Due after five years through ten years 0
Total debt securities $ 8,448
v3.25.1
Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)
$ in Millions
Mar. 30, 2025
USD ($)
Mar. 30, 2025
EUR (€)
Dec. 29, 2024
USD ($)
Financial Liabilities      
Current Debt $ 13,897   $ 5,983
Non-Current Debt      
Non-Current Debt 38,355   $ 30,651
Unsecured Notes      
Non-Current Debt      
Debt instrument, face amount 9,200    
Carrying Amount      
Financial Liabilities      
Current Debt 13,897    
Non-Current Debt      
Non-Current Debt 38,355    
Estimated Fair Value      
Financial Liabilities      
Current Debt 13,855    
Non-Current Debt      
Non-Current Debt $ 36,406    
2.95% Notes due 2027      
Non-Current Debt      
Stated interest rate (as a percent) 2.95% 2.95%  
2.95% Notes due 2027 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 950    
2.95% Notes due 2027 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 980    
0.95% Notes due 2027      
Non-Current Debt      
Stated interest rate (as a percent) 0.95% 0.95%  
0.95% Notes due 2027 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,479    
0.95% Notes due 2027 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,395    
4.50% Notes due 2027      
Non-Current Debt      
Stated interest rate (as a percent) 4.50% 4.50%  
4.50% Notes due 2027 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 749    
4.50% Notes due 2027 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 757    
2.90% Notes due 2028      
Non-Current Debt      
Stated interest rate (as a percent) 2.90% 2.90%  
2.90% Notes due 2028 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,498    
2.90% Notes due 2028 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,452    
1.150% Notes due 2028 (750MM Euro 1.0784)      
Non-Current Debt      
Stated interest rate (as a percent) 1.15% 1.15%  
Debt instrument, face amount | €   € 750,000,000  
Foreign exchange rate 1.0784 1.0784  
1.150% Notes due 2028 (750MM Euro 1.0784) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 806    
1.150% Notes due 2028 (750MM Euro 1.0784) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 772    
4.55% Notes Due 2029      
Non-Current Debt      
Stated interest rate (as a percent) 4.55% 4.55%  
4.55% Notes Due 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 748    
4.55% Notes Due 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 758    
4.80% Notes due 2029      
Non-Current Debt      
Stated interest rate (as a percent) 4.80% 4.80%  
4.80% Notes due 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,146    
4.80% Notes due 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,175    
6.95% Notes due 2029      
Non-Current Debt      
Stated interest rate (as a percent) 6.95% 6.95%  
6.95% Notes due 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 299    
6.95% Notes due 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 334    
2.700% Notes Due February 2029      
Non-Current Debt      
Stated interest rate (as a percent) 2.70% 2.70%  
Debt instrument, face amount | €   € 600,000,000  
Foreign exchange rate 1.0784 1.0784  
2.700% Notes Due February 2029 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 646    
2.700% Notes Due February 2029 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 648    
1.30% Notes due 2030      
Non-Current Debt      
Stated interest rate (as a percent) 1.30% 1.30%  
1.30% Notes due 2030 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,672    
1.30% Notes due 2030 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,499    
4.70% Notes due 2030      
Non-Current Debt      
Stated interest rate (as a percent) 4.70% 4.70%  
4.70% Notes due 2030 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 995    
4.70% Notes due 2030 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,017    
4.90% Notes due 2031      
Non-Current Debt      
Stated interest rate (as a percent) 4.90% 4.90%  
4.90% Notes due 2031 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,146    
4.90% Notes due 2031 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,178    
3.20% Notes due 2032 (700MM Euro 1.0721)      
Non-Current Debt      
Stated interest rate (as a percent) 3.20% 3.20%  
Debt instrument, face amount | €   € 700,000,000  
Foreign exchange rate 1.0784 1.0784  
3.20% Notes due 2032 (700MM Euro 1.0721) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 752    
3.20% Notes due 2032 (700MM Euro 1.0721) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 762    
4.85% Notes Due 2032      
Non-Current Debt      
Stated interest rate (as a percent) 4.85% 4.85%  
4.85% Notes Due 2032 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,242    
4.85% Notes Due 2032 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,268    
4.95% Notes due 2033      
Non-Current Debt      
Stated interest rate (as a percent) 4.95% 4.95%  
4.95% Notes due 2033 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 499    
4.95% Notes due 2033 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 514    
4.375% Notes due 2033      
Non-Current Debt      
Stated interest rate (as a percent) 4.375% 4.375%  
4.375% Notes due 2033 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 854    
4.375% Notes due 2033 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt 838    
3.050% Notes Due February 2033 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 752    
Stated interest rate (as a percent) 3.05% 3.05%  
Debt instrument, face amount | €   € 700,000,000  
Foreign exchange rate 1.0784 1.0784  
3.050% Notes Due February 2033 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 749    
4.95% Notes due 2034      
Non-Current Debt      
Stated interest rate (as a percent) 4.95% 4.95%  
4.95% Notes due 2034 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 846    
4.95% Notes due 2034 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt 870    
1.650% Notes due 2035 (1.5B Euro 1.0784) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,607    
Stated interest rate (as a percent) 1.65% 1.65%  
Debt instrument, face amount | €   € 1,500,000,000  
Foreign exchange rate 1.0784 1.0784  
1.650% Notes due 2035 (1.5B Euro 1.0784) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,393    
5.00% Notes due 2035      
Non-Current Debt      
Stated interest rate (as a percent) 5.00% 5.00%  
5.00% Notes due 2035 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,243    
5.00% Notes due 2035 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,270    
3.35% Notes Due 2036 (800MM Euro 1.0721)      
Non-Current Debt      
Stated interest rate (as a percent) 3.35% 3.35%  
Debt instrument, face amount | €   € 800,000,000  
Foreign exchange rate 1.0784 1.0784  
3.35% Notes Due 2036 (800MM Euro 1.0721) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 858    
3.35% Notes Due 2036 (800MM Euro 1.0721) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 849    
3.587% Notes due 2036      
Non-Current Debt      
Stated interest rate (as a percent) 3.587% 3.587%  
3.587% Notes due 2036 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 897    
3.587% Notes due 2036 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 894    
5.95% Notes due 2037      
Non-Current Debt      
Stated interest rate (as a percent) 5.95% 5.95%  
5.95% Notes due 2037 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 994    
5.95% Notes due 2037 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,094    
3.625% Notes due 2037      
Non-Current Debt      
Stated interest rate (as a percent) 3.625% 3.625%  
3.625% Notes due 2037 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,387    
3.625% Notes due 2037 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,333    
3.350% Notes Due February 2037      
Non-Current Debt      
Stated interest rate (as a percent) 3.35% 3.35%  
Debt instrument, face amount | €   € 1,000,000,000.0  
Foreign exchange rate 1.0784 1.0784  
3.350% Notes Due February 2037 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,075    
3.350% Notes Due February 2037 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,058    
3.40% Notes due 2038      
Non-Current Debt      
Stated interest rate (as a percent) 3.40% 3.40%  
3.40% Notes due 2038 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 993    
3.40% Notes due 2038 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 855    
5.85% Notes due 2038      
Non-Current Debt      
Stated interest rate (as a percent) 5.85% 5.85%  
5.85% Notes due 2038 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 697    
5.85% Notes due 2038 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 760    
4.50% Notes due 2040      
Non-Current Debt      
Stated interest rate (as a percent) 4.50% 4.50%  
4.50% Notes due 2040 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 542    
4.50% Notes due 2040 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 524    
2.10% Notes due 2040      
Non-Current Debt      
Stated interest rate (as a percent) 2.10% 2.10%  
2.10% Notes due 2040 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 874    
2.10% Notes due 2040 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 689    
4.85% Notes due 2041      
Non-Current Debt      
Stated interest rate (as a percent) 4.85% 4.85%  
4.85% Notes due 2041 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 298    
4.85% Notes due 2041 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 293    
4.50% Notes due 2043      
Non-Current Debt      
Stated interest rate (as a percent) 4.50% 4.50%  
4.50% Notes due 2043 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 496    
4.50% Notes due 2043 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 464    
3.55% Notes Due 2044 (1.0B Euro 1.0721)      
Non-Current Debt      
Stated interest rate (as a percent) 3.55% 3.55%  
Debt instrument, face amount | €   € 1,000,000,000.0  
Foreign exchange rate 1.0784 1.0784  
3.55% Notes Due 2044 (1.0B Euro 1.0721) | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,068    
3.55% Notes Due 2044 (1.0B Euro 1.0721) | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,037    
3.600% Notes Due February 2045      
Non-Current Debt      
Stated interest rate (as a percent) 3.60% 3.60%  
Debt instrument, face amount | €   € 700,000,000  
Foreign exchange rate 1.0784 1.0784  
3.600% Notes Due February 2045 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 749    
3.600% Notes Due February 2045 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 723    
3.73% Notes due 2046      
Non-Current Debt      
Stated interest rate (as a percent) 3.73% 3.73%  
3.73% Notes due 2046 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,979    
3.73% Notes due 2046 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,604    
3.75% Notes due 2047      
Non-Current Debt      
Stated interest rate (as a percent) 3.75% 3.75%  
3.75% Notes due 2047 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 852    
3.75% Notes due 2047 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 802    
3.50% Notes due 2048      
Non-Current Debt      
Stated interest rate (as a percent) 3.50% 3.50%  
3.50% Notes due 2048 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 744    
3.50% Notes due 2048 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 569    
2.25% Notes due 2050      
Non-Current Debt      
Stated interest rate (as a percent) 2.25% 2.25%  
2.25% Notes due 2050 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 837    
2.25% Notes due 2050 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 582    
5.25% Notes due 2054      
Non-Current Debt      
Stated interest rate (as a percent) 5.25% 5.25%  
5.25% Notes due 2054 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 843    
5.25% Notes due 2054 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 850    
3.700% Notes Due February 2055      
Non-Current Debt      
Stated interest rate (as a percent) 3.70% 3.70%  
Debt instrument, face amount | €   € 1,000,000,000.0  
Foreign exchange rate 1.0784 1.0784  
3.700% Notes Due February 2055 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,072    
3.700% Notes Due February 2055 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 1,020    
2.45% Notes due 2060      
Non-Current Debt      
Stated interest rate (as a percent) 2.45% 2.45%  
2.45% Notes due 2060 | Carrying Amount      
Non-Current Debt      
Non-Current Debt $ 1,088    
2.45% Notes due 2060 | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt 694    
Other | Carrying Amount      
Non-Current Debt      
Non-Current Debt 83    
Other | Estimated Fair Value      
Non-Current Debt      
Non-Current Debt $ 83    
v3.25.1
Income Taxes (Details) - USD ($)
$ in Billions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Income Tax Contingency    
Worldwide effective income tax rate (as a percent) 19.30% 12.40%
Effective income tax rate reconciliation, tax settlement, percent 22.00% 22.00%
Unrecognized tax benefits $ 2.1  
Talc | Consumer    
Income Tax Contingency    
Reversal of fee expense $ 7.0  
Litigation expense   $ 2.7
v3.25.1
Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Retirement Plans    
Components of net periodic benefit cost    
Service cost $ 214 $ 224
Interest cost 351 352
Expected return on plan assets (587) (642)
Amortization of prior service cost/‍(credit) (46) (46)
Recognized actuarial (gains)/losses 83 43
Net periodic benefit cost/(credit) 15 (69)
Other Benefit Plans    
Components of net periodic benefit cost    
Service cost 72 69
Interest cost 54 52
Expected return on plan assets (2) (2)
Amortization of prior service cost/‍(credit) 0 0
Recognized actuarial (gains)/losses 16 13
Net periodic benefit cost/(credit) $ 140 $ 132
v3.25.1
Pensions and Other Benefit Plans (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2025
USD ($)
U.S.  
Defined Benefit Plan Disclosure [Line Items]  
Contribution to pension plans $ 34
Foreign Plan  
Defined Benefit Plan Disclosure [Line Items]  
Contribution to pension plans $ 4
v3.25.1
Accumulated Other Comprehensive Income (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2025
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance $ 71,490
Net change 1
Ending balance 78,109
Foreign Currency Translation  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (8,441)
Net change (575)
Ending balance (9,016)
Gain/ (Loss) On Securities  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance 1
Net change 0
Ending balance 1
Employee Benefit Plans  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (1,551)
Net change 42
Ending balance (1,509)
Gain/ (Loss) On Derivatives & Hedges  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (1,750)
Net change 534
Ending balance (1,216)
Total Accumulated Other Comprehensive Income/(Loss)  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (11,741)
Ending balance $ (11,740)
v3.25.1
Earnings Per Share (Details) - $ / shares
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Reconciliation of basic net earnings per share to diluted net earnings per share    
Total net earnings per share - basic (in dollars per share) $ 4.57 $ 1.35
Average shares outstanding — basic 2,407,200,000 2,408,200,000
Potential shares exercisable under stock option plans 69,000,000.0 87,600,000
Less: shares which could be repurchased under treasury stock method (52,400,000) (65,700,000)
Average shares outstanding — diluted 2,423,800,000 2,430,100,000
Total net earnings per share - diluted (in dollars per share) $ 4.54 $ 1.34
Antidilutive securities excluded from computation of earnings per share, amount 60.9 44.2
v3.25.1
Segments of Business and Geographic Areas - Narrative (Details)
 3 Months Ended
Mar. 30, 2025
segment
Segment Reporting [Abstract]  
Number of operating segments 2
v3.25.1
Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Sales by segment of business    
Sales to customers $ 21,893 $ 21,383
Percent Change (as a percent) 2.40%  
U.S.    
Sales by segment of business    
Sales to customers $ 12,305 11,620
Percent Change (as a percent) 5.90%  
International    
Sales by segment of business    
Sales to customers $ 9,588 9,763
Percent Change (as a percent) (1.80%)  
Innovative Medicine    
Sales by segment of business    
Sales to customers $ 13,873 13,562
Percent Change (as a percent) 2.30%  
Innovative Medicine | U.S.    
Sales by segment of business    
Sales to customers $ 8,092 7,612
Percent Change (as a percent) 6.30%  
Innovative Medicine | International    
Sales by segment of business    
Sales to customers $ 5,781 5,950
Percent Change (as a percent) (2.90%)  
Innovative Medicine | Oncology    
Sales by segment of business    
Sales to customers $ 5,678 4,814
Percent Change (as a percent) 17.90%  
Innovative Medicine | Oncology | U.S.    
Sales by segment of business    
Sales to customers $ 3,013 2,383
Percent Change (as a percent) 26.40%  
Innovative Medicine | Oncology | International    
Sales by segment of business    
Sales to customers $ 2,664 2,430
Percent Change (as a percent) 9.60%  
Innovative Medicine | Oncology | CARVYKTI    
Sales by segment of business    
Sales to customers $ 369 157
Innovative Medicine | Oncology | CARVYKTI | U.S.    
Sales by segment of business    
Sales to customers 318 140
Innovative Medicine | Oncology | CARVYKTI | International    
Sales by segment of business    
Sales to customers 51 16
Innovative Medicine | Oncology | DARZALEX    
Sales by segment of business    
Sales to customers $ 3,237 2,692
Percent Change (as a percent) 20.30%  
Innovative Medicine | Oncology | DARZALEX | U.S.    
Sales by segment of business    
Sales to customers $ 1,829 1,464
Percent Change (as a percent) 24.90%  
Innovative Medicine | Oncology | DARZALEX | International    
Sales by segment of business    
Sales to customers $ 1,409 1,228
Percent Change (as a percent) 14.70%  
Innovative Medicine | Oncology | ERLEADA    
Sales by segment of business    
Sales to customers $ 771 689
Percent Change (as a percent) 11.90%  
Innovative Medicine | Oncology | ERLEADA | U.S.    
Sales by segment of business    
Sales to customers $ 292 285
Percent Change (as a percent) 2.50%  
Innovative Medicine | Oncology | ERLEADA | International    
Sales by segment of business    
Sales to customers $ 479 404
Percent Change (as a percent) 18.50%  
Innovative Medicine | Oncology | IMBRUVICA    
Sales by segment of business    
Sales to customers $ 709 784
Percent Change (as a percent) (9.50%)  
Innovative Medicine | Oncology | IMBRUVICA | U.S.    
Sales by segment of business    
Sales to customers $ 235 265
Percent Change (as a percent) (11.50%)  
Innovative Medicine | Oncology | IMBRUVICA | International    
Sales by segment of business    
Sales to customers $ 474 518
Percent Change (as a percent) (8.50%)  
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE    
Sales by segment of business    
Sales to customers $ 141 47
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | U.S.    
Sales by segment of business    
Sales to customers 113 36
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | International    
Sales by segment of business    
Sales to customers 28 11
Innovative Medicine | Oncology | TALVEY    
Sales by segment of business    
Sales to customers $ 86 58
Percent Change (as a percent) 48.40%  
Innovative Medicine | Oncology | TALVEY | U.S.    
Sales by segment of business    
Sales to customers $ 68 50
Percent Change (as a percent) 35.20%  
Innovative Medicine | Oncology | TALVEY | International    
Sales by segment of business    
Sales to customers $ 18 8
Innovative Medicine | Oncology | Tecvayli    
Sales by segment of business    
Sales to customers $ 151 133
Percent Change (as a percent) 13.30%  
Innovative Medicine | Oncology | Tecvayli | U.S.    
Sales by segment of business    
Sales to customers $ 105 101
Percent Change (as a percent) 4.90%  
Innovative Medicine | Oncology | Tecvayli | International    
Sales by segment of business    
Sales to customers $ 46 33
Percent Change (as a percent) 38.80%  
Innovative Medicine | Oncology | ZYTIGA    
Sales by segment of business    
Sales to customers $ 125 181
Percent Change (as a percent) (30.90%)  
Innovative Medicine | Oncology | ZYTIGA | U.S.    
Sales by segment of business    
Sales to customers $ 7 9
Percent Change (as a percent) (24.30%)  
Innovative Medicine | Oncology | ZYTIGA | International    
Sales by segment of business    
Sales to customers $ 118 172
Percent Change (as a percent) (31.30%)  
Innovative Medicine | Oncology | Other Oncology    
Sales by segment of business    
Sales to customers $ 89 73
Percent Change (as a percent) 21.70%  
Innovative Medicine | Oncology | Other Oncology | U.S.    
Sales by segment of business    
Sales to customers $ 47 33
Percent Change (as a percent) 42.90%  
Innovative Medicine | Oncology | Other Oncology | International    
Sales by segment of business    
Sales to customers $ 42 41
Percent Change (as a percent) 4.60%  
Innovative Medicine | Immunology    
Sales by segment of business    
Sales to customers $ 3,707 4,247
Percent Change (as a percent) (12.70%)  
Innovative Medicine | Immunology | U.S.    
Sales by segment of business    
Sales to customers $ 2,196 2,453
Percent Change (as a percent) (10.50%)  
Innovative Medicine | Immunology | International    
Sales by segment of business    
Sales to customers $ 1,510 1,794
Percent Change (as a percent) (15.80%)  
Innovative Medicine | Immunology | REMICADE    
Sales by segment of business    
Sales to customers $ 467 434
Percent Change (as a percent) 7.50%  
Innovative Medicine | Immunology | REMICADE | U.S.    
Sales by segment of business    
Sales to customers $ 314 266
Percent Change (as a percent) 18.10%  
Innovative Medicine | Immunology | REMICADE | U.S. Exports    
Sales by segment of business    
Sales to customers $ 10 27
Percent Change (as a percent) (64.20%)  
Innovative Medicine | Immunology | REMICADE | International    
Sales by segment of business    
Sales to customers $ 143 141
Percent Change (as a percent) 1.30%  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA    
Sales by segment of business    
Sales to customers $ 659 554
Percent Change (as a percent) 18.90%  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S.    
Sales by segment of business    
Sales to customers $ 292 254
Percent Change (as a percent) 14.80%  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International    
Sales by segment of business    
Sales to customers $ 366 299
Percent Change (as a percent) 22.40%  
Innovative Medicine | Immunology | STELARA    
Sales by segment of business    
Sales to customers $ 1,625 2,451
Percent Change (as a percent) (33.70%)  
Innovative Medicine | Immunology | STELARA | U.S.    
Sales by segment of business    
Sales to customers $ 981 1,396
Percent Change (as a percent) (29.80%)  
Innovative Medicine | Immunology | STELARA | International    
Sales by segment of business    
Sales to customers $ 644 1,055
Percent Change (as a percent) (38.90%)  
Innovative Medicine | Immunology | TREMFYA    
Sales by segment of business    
Sales to customers $ 956 808
Percent Change (as a percent) 18.20%  
Innovative Medicine | Immunology | TREMFYA | U.S.    
Sales by segment of business    
Sales to customers $ 599 509
Percent Change (as a percent) 17.60%  
Innovative Medicine | Immunology | TREMFYA | International    
Sales by segment of business    
Sales to customers $ 356 299
Percent Change (as a percent) 19.20%  
Innovative Medicine | Immunology | OTHER IMMUNOLOGY    
Sales by segment of business    
Sales to customers $ 1 0
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S.    
Sales by segment of business    
Sales to customers 1 0
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International    
Sales by segment of business    
Sales to customers $ 0 0
Percent Change (as a percent) 0.00%  
Innovative Medicine | Infectious Diseases    
Sales by segment of business    
Sales to customers $ 802 821
Percent Change (as a percent) (2.20%)  
Innovative Medicine | Infectious Diseases | U.S.    
Sales by segment of business    
Sales to customers $ 315 324
Percent Change (as a percent) (2.80%)  
Innovative Medicine | Infectious Diseases | International    
Sales by segment of business    
Sales to customers $ 487 497
Percent Change (as a percent) (1.90%)  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine    
Sales by segment of business    
Sales to customers $ 358 323
Percent Change (as a percent) 10.70%  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | U.S.    
Sales by segment of business    
Sales to customers $ 8 8
Percent Change (as a percent) (1.30%)  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | International    
Sales by segment of business    
Sales to customers $ 350 315
Percent Change (as a percent) 11.00%  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA    
Sales by segment of business    
Sales to customers $ 403 418
Percent Change (as a percent) (3.70%)  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | U.S.    
Sales by segment of business    
Sales to customers $ 305 314
Percent Change (as a percent) (2.90%)  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | International    
Sales by segment of business    
Sales to customers $ 98 104
Percent Change (as a percent) (6.20%)  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES    
Sales by segment of business    
Sales to customers $ 41 78
Percent Change (as a percent) (47.60%)  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.    
Sales by segment of business    
Sales to customers $ 2 2
Percent Change (as a percent) 7.70%  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International    
Sales by segment of business    
Sales to customers $ 39 77
Percent Change (as a percent) (48.80%)  
Innovative Medicine | Neuroscience    
Sales by segment of business    
Sales to customers $ 1,647 1,803
Percent Change (as a percent) (8.60%)  
Innovative Medicine | Neuroscience | U.S.    
Sales by segment of business    
Sales to customers $ 968 1,054
Percent Change (as a percent) (8.10%)  
Innovative Medicine | Neuroscience | International    
Sales by segment of business    
Sales to customers $ 679 749
Percent Change (as a percent) (9.30%)  
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate    
Sales by segment of business    
Sales to customers $ 148 177
Percent Change (as a percent) (16.30%)  
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S.    
Sales by segment of business    
Sales to customers $ 38 41
Percent Change (as a percent) (7.40%)  
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International    
Sales by segment of business    
Sales to customers $ 110 136
Percent Change (as a percent) (18.90%)  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA    
Sales by segment of business    
Sales to customers $ 903 1,056
Percent Change (as a percent) (14.50%)  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.    
Sales by segment of business    
Sales to customers $ 625 765
Percent Change (as a percent) (18.20%)  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International    
Sales by segment of business    
Sales to customers $ 277 292
Percent Change (as a percent) (4.90%)  
Innovative Medicine | Neuroscience | SPRAVATO    
Sales by segment of business    
Sales to customers $ 320 225
Percent Change (as a percent) 41.90%  
Innovative Medicine | Neuroscience | SPRAVATO | U.S.    
Sales by segment of business    
Sales to customers $ 276 191
Percent Change (as a percent) 45.00%  
Innovative Medicine | Neuroscience | SPRAVATO | International    
Sales by segment of business    
Sales to customers $ 43 34
Percent Change (as a percent) 25.00%  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE    
Sales by segment of business    
Sales to customers $ 277 345
Percent Change (as a percent) (19.60%)  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S.    
Sales by segment of business    
Sales to customers $ 28 58
Percent Change (as a percent) (50.60%)  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International    
Sales by segment of business    
Sales to customers $ 248 287
Percent Change (as a percent) (13.40%)  
Innovative Medicine | Pulmonary Hypertension    
Sales by segment of business    
Sales to customers $ 1,025 1,049
Percent Change (as a percent) (2.30%)  
Innovative Medicine | Pulmonary Hypertension | U.S.    
Sales by segment of business    
Sales to customers $ 744 766
Percent Change (as a percent) (2.90%)  
Innovative Medicine | Pulmonary Hypertension | International    
Sales by segment of business    
Sales to customers $ 281 283
Percent Change (as a percent) (0.60%)  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI(2)    
Sales by segment of business    
Sales to customers $ 522 524
Percent Change (as a percent) (0.50%)  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI(2) | U.S.    
Sales by segment of business    
Sales to customers $ 363 356
Percent Change (as a percent) 2.10%  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI(2) | International    
Sales by segment of business    
Sales to customers $ 159 169
Percent Change (as a percent) (6.00%)  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI    
Sales by segment of business    
Sales to customers $ 451 468
Percent Change (as a percent) (3.60%)  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S.    
Sales by segment of business    
Sales to customers $ 365 392
Percent Change (as a percent) (6.90%)  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International    
Sales by segment of business    
Sales to customers $ 86 76
Percent Change (as a percent) 13.40%  
Innovative Medicine | Pulmonary Hypertension | Other    
Sales by segment of business    
Sales to customers $ 52 56
Percent Change (as a percent) (7.20%)  
Innovative Medicine | Pulmonary Hypertension | Other | U.S.    
Sales by segment of business    
Sales to customers $ 15 18
Percent Change (as a percent) (12.70%)  
Innovative Medicine | Pulmonary Hypertension | Other | International    
Sales by segment of business    
Sales to customers $ 37 39
Percent Change (as a percent) (4.60%)  
Innovative Medicine | Cardiovascular / Metabolism / Other    
Sales by segment of business    
Sales to customers $ 1,013 829
Percent Change (as a percent) 22.30%  
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S.    
Sales by segment of business    
Sales to customers $ 855 631
Percent Change (as a percent) 35.40%  
Innovative Medicine | Cardiovascular / Metabolism / Other | International    
Sales by segment of business    
Sales to customers $ 158 197
Percent Change (as a percent) (19.70%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other    
Sales by segment of business    
Sales to customers $ 323 311
Percent Change (as a percent) 3.90%  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S.    
Sales by segment of business    
Sales to customers $ 165 114
Percent Change (as a percent) 45.00%  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International    
Sales by segment of business    
Sales to customers $ 158 197
Percent Change (as a percent) (19.70%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO    
Sales by segment of business    
Sales to customers $ 690 518
Percent Change (as a percent) 33.30%  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S.    
Sales by segment of business    
Sales to customers $ 690 518
Percent Change (as a percent) 33.30%  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International    
Sales by segment of business    
Sales to customers $ 0 0
Percent Change (as a percent) 0.00%  
MEDTECH    
Sales by segment of business    
Sales to customers $ 8,020 7,821
Percent Change (as a percent) 2.50%  
MEDTECH | U.S.    
Sales by segment of business    
Sales to customers $ 4,213 4,008
Percent Change (as a percent) 5.10%  
MEDTECH | International    
Sales by segment of business    
Sales to customers $ 3,807 3,813
Percent Change (as a percent) (0.20%)  
MEDTECH | Cardiovascular    
Sales by segment of business    
Sales to customers $ 2,103 1,806
Percent Change (as a percent) 16.40%  
MEDTECH | Cardiovascular | U.S.    
Sales by segment of business    
Sales to customers $ 1,261 1,025
Percent Change (as a percent) 23.00%  
MEDTECH | Cardiovascular | International    
Sales by segment of business    
Sales to customers $ 842 781
Percent Change (as a percent) 7.80%  
MEDTECH | ELECTROPHYSIOLOGY    
Sales by segment of business    
Sales to customers $ 1,323 1,344
Percent Change (as a percent) (1.60%)  
MEDTECH | ELECTROPHYSIOLOGY | U.S.    
Sales by segment of business    
Sales to customers $ 684 692
Percent Change (as a percent) (1.10%)  
MEDTECH | ELECTROPHYSIOLOGY | International    
Sales by segment of business    
Sales to customers $ 638 652
Percent Change (as a percent) (2.00%)  
MEDTECH | ABIOMED    
Sales by segment of business    
Sales to customers $ 420 371
Percent Change (as a percent) 13.30%  
MEDTECH | ABIOMED | U.S.    
Sales by segment of business    
Sales to customers $ 339 303
Percent Change (as a percent) 11.90%  
MEDTECH | ABIOMED | International    
Sales by segment of business    
Sales to customers $ 81 67
Percent Change (as a percent) 19.70%  
MEDTECH | Shockwave    
Sales by segment of business    
Sales to customers $ 258 0
MEDTECH | Shockwave | U.S.    
Sales by segment of business    
Sales to customers 206 0
MEDTECH | Shockwave | International    
Sales by segment of business    
Sales to customers 52 0
MEDTECH | Other Cardiovascular    
Sales by segment of business    
Sales to customers $ 103 92
Percent Change (as a percent) 12.50%  
MEDTECH | Other Cardiovascular | U.S.    
Sales by segment of business    
Sales to customers $ 32 30
Percent Change (as a percent) 7.10%  
MEDTECH | Other Cardiovascular | International    
Sales by segment of business    
Sales to customers $ 72 62
Percent Change (as a percent) 15.10%  
MEDTECH | Orthopaedics    
Sales by segment of business    
Sales to customers $ 2,241 2,340
Percent Change (as a percent) (4.20%)  
MEDTECH | Orthopaedics | U.S.    
Sales by segment of business    
Sales to customers $ 1,384 1,448
Percent Change (as a percent) (4.40%)  
MEDTECH | Orthopaedics | International    
Sales by segment of business    
Sales to customers $ 857 892
Percent Change (as a percent) (3.90%)  
MEDTECH | Orthopaedics | HIPS    
Sales by segment of business    
Sales to customers $ 409 422
Percent Change (as a percent) (3.10%)  
MEDTECH | Orthopaedics | HIPS | U.S.    
Sales by segment of business    
Sales to customers $ 263 270
Percent Change (as a percent) (2.50%)  
MEDTECH | Orthopaedics | HIPS | International    
Sales by segment of business    
Sales to customers $ 146 152
Percent Change (as a percent) (4.00%)  
MEDTECH | Orthopaedics | KNEES    
Sales by segment of business    
Sales to customers $ 389 401
Percent Change (as a percent) (3.00%)  
MEDTECH | Orthopaedics | KNEES | U.S.    
Sales by segment of business    
Sales to customers $ 231 242
Percent Change (as a percent) (4.30%)  
MEDTECH | Orthopaedics | KNEES | International    
Sales by segment of business    
Sales to customers $ 158 160
Percent Change (as a percent) (1.00%)  
MEDTECH | Orthopaedics | TRAUMA    
Sales by segment of business    
Sales to customers $ 772 765
Percent Change (as a percent) 0.90%  
MEDTECH | Orthopaedics | TRAUMA | U.S.    
Sales by segment of business    
Sales to customers $ 502 504
Percent Change (as a percent) (0.50%)  
MEDTECH | Orthopaedics | TRAUMA | International    
Sales by segment of business    
Sales to customers $ 270 261
Percent Change (as a percent) 3.70%  
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER    
Sales by segment of business    
Sales to customers $ 671 752
Percent Change (as a percent) (10.80%)  
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S.    
Sales by segment of business    
Sales to customers $ 388 432
Percent Change (as a percent) (10.20%)  
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International    
Sales by segment of business    
Sales to customers $ 283 320
Percent Change (as a percent) (11.60%)  
MEDTECH | Surgery    
Sales by segment of business    
Sales to customers $ 2,396 2,416
Percent Change (as a percent) (0.80%)  
MEDTECH | Surgery | U.S.    
Sales by segment of business    
Sales to customers $ 1,002 987
Percent Change (as a percent) 1.50%  
MEDTECH | Surgery | International    
Sales by segment of business    
Sales to customers $ 1,394 1,429
Percent Change (as a percent) (2.50%)  
MEDTECH | Surgery | ADVANCED    
Sales by segment of business    
Sales to customers $ 1,073 1,087
Percent Change (as a percent) (1.20%)  
MEDTECH | Surgery | ADVANCED | U.S.    
Sales by segment of business    
Sales to customers $ 457 446
Percent Change (as a percent) 2.70%  
MEDTECH | Surgery | ADVANCED | International    
Sales by segment of business    
Sales to customers $ 616 641
Percent Change (as a percent) (4.00%)  
MEDTECH | Surgery | GENERAL    
Sales by segment of business    
Sales to customers $ 1,323 1,330
Percent Change (as a percent) (0.50%)  
MEDTECH | Surgery | GENERAL | U.S.    
Sales by segment of business    
Sales to customers $ 544 542
Percent Change (as a percent) 0.50%  
MEDTECH | Surgery | GENERAL | International    
Sales by segment of business    
Sales to customers $ 778 788
Percent Change (as a percent) (1.20%)  
MEDTECH | Vision    
Sales by segment of business    
Sales to customers $ 1,279 1,258
Percent Change (as a percent) 1.70%  
MEDTECH | Vision | U.S.    
Sales by segment of business    
Sales to customers $ 566 547
Percent Change (as a percent) 3.40%  
MEDTECH | Vision | International    
Sales by segment of business    
Sales to customers $ 713 710
Percent Change (as a percent) 0.40%  
MEDTECH | Vision | CONTACT LENSES / OTHER    
Sales by segment of business    
Sales to customers $ 919 910
Percent Change (as a percent) 1.00%  
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S.    
Sales by segment of business    
Sales to customers $ 452 438
Percent Change (as a percent) 3.10%  
MEDTECH | Vision | CONTACT LENSES / OTHER | International    
Sales by segment of business    
Sales to customers $ 467 472
Percent Change (as a percent) (1.10%)  
MEDTECH | Vision | SURGICAL    
Sales by segment of business    
Sales to customers $ 361 348
Percent Change (as a percent) 3.70%  
MEDTECH | Vision | SURGICAL | U.S.    
Sales by segment of business    
Sales to customers $ 114 110
Percent Change (as a percent) 4.30%  
MEDTECH | Vision | SURGICAL | International    
Sales by segment of business    
Sales to customers $ 246 $ 238
Percent Change (as a percent) 3.40%  
v3.25.1
Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) $ 21,893 $ 21,383
Cost of products sold 7,357 6,511
Gross Profit 14,536 14,872
Selling, marketing and administrative expenses 5,112 5,257
Research and development expense 3,225 3,542
Other (income) expense, net 7,321 (2,404)
Earnings before provision for taxes on income 13,631 3,714
Less: Expense not allocated to segments (7,000) 2,775
Restructuring charges 17 164
Innovative Medicine    
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) 13,873 13,562
Restructuring charges 100  
MedTech    
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) 8,020 7,821
Restructuring charges 100  
Acquisition related costs 100 100
Consumer | Talc    
Segment Reporting Information [Line Items]    
Litigation expense   2,700
Reversal of fee expense 7,000  
Operating Segments    
Segment Reporting Information [Line Items]    
Earnings before provision for taxes on income 6,631 6,489
Restructuring charges 55 171
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) 13,873 13,562
Cost of products sold 4,020 3,370
Selling, marketing and administrative expenses 2,261 2,438
Research and development expense 2,548 2,896
Other (income) expense, net (166) (111)
Earnings before provision for taxes on income 5,210 4,969
Amortization 600 700
Restructuring charges 0 144
Operating Segments | MedTech    
Segment Reporting Information [Line Items]    
Sales to customers (Note 9) 8,020 7,821
Cost of products sold 3,326 3,120
Selling, marketing and administrative expenses 2,656 2,582
Research and development expense 677 646
Other (income) expense, net (60) (47)
Earnings before provision for taxes on income 1,421 1,520
Amortization 500 400
Restructuring charges $ 55 $ 27
v3.25.1
Segments of Business and Geographic Areas - Identifiable Assets (Details) - USD ($)
$ in Millions
Mar. 30, 2025
Dec. 29, 2024
Segment Reporting Information [Line Items]    
Assets $ 193,671 $ 180,104
Segments Total    
Segment Reporting Information [Line Items]    
Assets 143,838 141,392
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Assets 58,727 57,070
Operating Segments | MEDTECH    
Segment Reporting Information [Line Items]    
Assets 85,111 84,322
Corporate, Non-Segment | General Corporate    
Segment Reporting Information [Line Items]    
Assets $ 49,833 $ 38,712
v3.25.1
Segments of Business and Geographic Areas - Additions to Property, Plan & Equipment and Depreciation and Amortization (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment $ 795 $ 807
Depreciation and Amortization 1,772 1,815
Segments Total    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 756 725
Depreciation and Amortization 1,720 1,757
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 276 232
Depreciation and Amortization 884 1,011
Operating Segments | MEDTECH    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 480 493
Depreciation and Amortization 836 746
Corporate, Non-Segment | General Corporate    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 39 82
Depreciation and Amortization $ 52 $ 58
v3.25.1
Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Sales by geographic area    
Sales $ 21,893 $ 21,383
Percent Change 2.40%  
United States    
Sales by geographic area    
Sales $ 12,305 11,620
Percent Change 5.90%  
Europe    
Sales by geographic area    
Sales $ 5,110 5,163
Percent Change (1.00%)  
Western Hemisphere, excluding U.S.    
Sales by geographic area    
Sales $ 1,167 1,194
Percent Change (2.30%)  
Asia-Pacific, Africa    
Sales by geographic area    
Sales $ 3,311 $ 3,406
Percent Change (2.80%)  
v3.25.1
Acquisitions and Divestitures (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Apr. 02, 2025
Jun. 20, 2024
May 31, 2024
Mar. 07, 2024
Mar. 30, 2025
Mar. 31, 2024
Dec. 29, 2024
Business Acquisition [Line Items]              
Payments to acquire businesses         $ 0 $ 1,811  
Goodwill, related to acquisitions         0    
Contingent consideration         1,231   $ 1,217
Proceeds from sale of business           $ 200  
Goodwill (Note 3)         44,468   $ 44,200
Proteologix              
Business Acquisition [Line Items]              
Payments to acquire businesses   $ 800          
Assets acquired   1,200          
Goodwill acquired   900          
Goodwill, related to acquisitions   300          
Liabilities assumed   300          
Contingent consideration   $ 100          
Acquisition related costs         0    
Shockwave Medical, Inc.              
Business Acquisition [Line Items]              
Payments to acquire businesses     $ 11,500        
Assets acquired     14,400        
Goodwill acquired     600        
Liabilities assumed     2,900        
Acquisition related costs         100    
Goodwill (Note 3)     7,600        
Finite-Lived intangibles assumed     5,300        
Assumed inventory     500        
Assumed other noncurrent assets     $ 400        
Ambrx              
Business Acquisition [Line Items]              
Payments to acquire businesses       $ 1,800      
Assets acquired       2,300      
Goodwill acquired       1,900      
Goodwill, related to acquisitions       300      
Liabilities assumed       500      
Acquisition related costs         $ 0    
Deferred tax liabilities assumed       $ 400      
Intra-Cellular Therapies, Inc. | Subsequent Event              
Business Acquisition [Line Items]              
Share price (in dollars per share) $ 132.00            
Consideration transferred $ 14,600            
v3.25.1
Legal Proceedings (Details)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
May 01, 2024
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jul. 31, 2018
USD ($)
Mar. 30, 2025
USD ($)
claimant
cases
Dec. 29, 2024
USD ($)
Sep. 30, 2021
cases
Jul. 04, 2021
USD ($)
May 31, 2021
claimant
cases
Physiomesh                  
Legal Proceeding (Textuals)                  
Product liability contingency, number of claimants | claimant         140        
Physiomesh | Pending Litigation                  
Legal Proceeding (Textuals)                  
Number of pending claims | cases                 3,600
Product liability contingency, number of claimants | claimant                 4,300
Number of claims within settlement agreement | cases             3,729    
Talc                  
Legal Proceeding (Textuals)                  
Product liability contingency, number of claimants | claimant         62,850        
Opioid                  
Legal Proceeding (Textuals)                  
Loss contingency accrual               $ 5,000  
Product liability contingency, number of claimants | claimant         3,500        
Loss contingency accrual, payment percentage         70.00%        
Opioid | Various State Courts                  
Legal Proceeding (Textuals)                  
Number of open cases | cases         35        
Opioid | Ohio Multi-District Litigation                  
Legal Proceeding (Textuals)                  
Number of open cases | cases         325        
Opioid | Federal Courts                  
Legal Proceeding (Textuals)                  
Number of open cases | cases         3        
Ingham v. Johnson & Johnson                  
Legal Proceeding (Textuals)                  
Damages awarded     $ 2,100 $ 4,700          
Damages paid   $ 2,500              
DePuy ASR U.S. | Settled Litigation                  
Legal Proceeding (Textuals)                  
Number of patients in settlement | claimant         10,000        
Talc                  
Legal Proceeding (Textuals)                  
Litigation contingency $ 6,475                
Payment period 25 years                
Damages sought, nominal value $ 8,000                
Bankruptcy loss contingency, discount rate 4.40%                
Total claims against company, percent 99.75%                
Incremental charges           $ 5,000      
Loss contingency accrual         $ 4,200 11,600      
Loss contingency accrual, nominal value           $ 13,500      
Loss contingency accrual, payment percentage         33.00%        
Solicitation period 3 months                
Talc | Consumer                  
Legal Proceeding (Textuals)                  
Reversal of fee expense         $ 7,000        
Mesothelioma and State Claims                  
Legal Proceeding (Textuals)                  
Claims settled, percent         95.00%        
v3.25.1
Legal Proceedings - Product Liability (Details)
Mar. 30, 2025
claimant
Talc  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 62,850
ASR  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 50
Pinnacle Acetabular Cup System  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 910
Pelvic Meshes  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 5,910
Physiomesh  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 140
Elmiron  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 1,140
v3.25.1
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 17 $ 164
Orthopedics Restructuring Plan    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges recorded to date 500  
Orthopedics Restructuring Plan | Minimum    
Restructuring Cost and Reserve [Line Items]    
Restructuring estimated cost 700  
Orthopedics Restructuring Plan | Maximum    
Restructuring Cost and Reserve [Line Items]    
Restructuring estimated cost $ 800  
v3.25.1
Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 17 $ 164
Operating Segments    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 55 171
MEDTECH    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 100  
MEDTECH | Operating Segments    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 55 27
MEDTECH | Restructuring Charges    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 17 20
MEDTECH | Costs of Goods and Services Sold    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 8 7
MEDTECH | Other Nonoperating Income (Expense)    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 30  
Innovative Medicine    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 100  
Innovative Medicine | Operating Segments    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 0 $ 144